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ABSTRACT 
 
 Breast carcinoma is the most common neoplasm affecting women worldwide, 
accounting for 25% of all malignancies diagnosed in 2012.  
 Iron is an essential microelement, vital for a variety of biological and cellular 
processes. However, iron is also considered to be potentially carcinogenic through several 
mechanisms, such as formation of mutagenic hydroxyl radicals, suppression of the host 
immune response and by acting as a limiting nutrient for proliferating tumor cells. 
Epidemiological, experimental and clinical evidences support the hypothesis that iron is 
strongly associated with breast cancer initiation, behavior and progression. Results from 
several studies provide evidence that cancer cells behave as iron deficient and are able to 
undermine the tightly physiological process of iron regulation.  
Accumulating evidence provides now a new insight about the role of stromal 
inflammatory cells in cancer. A multitude of studies reported that epithelial malignant cells 
require an appropriate support structure from stromal cells to successfully acquire a full 
malignant potential. The recruitment of inflammatory leukocytes into the tumor 
microenvironment involves the role of chemotactic cytokines.  
CCL2 (chemokine [(C-C motif)] ligand 2) is one of the most studied chemotactic cytokines 
in the context of tumor progression, particularly in breast cancer and its expression has 
been correlated with tumor progression and poor prognosis.  
 The aim of this work was to understand if the expression of CCL2, in the breast 
cancer model, could be related to tissue iron status.  More specifically, it assesses tissue 
iron deposition and CCL2 expression in epithelial and stromal inflammatory cells in well 
characterized breast cancer samples. Associations between CCL2 expression, established 
iron profiles and HFE variants were evaluated and CCL2 expression was also correlated 
with clinico-pathological parameters. 
 To address those aims, hemosiderin deposits in control and carcinoma samples, in 
epithelial and in stromal inflammatory cells, were identified by DAB-enhanced Perls’ staining 
technique. Immunohistochemistry was performed in order to assess the expression of CCL2 
in epithelial cells and macrophages; CD68 immunostaining was performed to assess total 
macrophage infiltration. PCR-RFLP was performed for the detection of the C282Y and 
H63D HFE allele variants. 
 Comparing with normal samples, a higher proportion of carcinoma samples 
presented iron deposition in epithelial and stromal inflammatory cells. The presence of 
hemosiderin deposits in macrophages and/or lymphocytes was statistically associated with 
increased malignancy. Epithelial CCL2 expression was not associated with total 
macrophage infiltration, but was statistically associated with the infiltration of CCL2-positive 
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macrophages. Ferroportin 1 (FPN 1) expression in macrophages and lymphocytes was 
found to be increased in carcinoma samples, in comparison to normal cases. Furthermore, 
the median expression of CCL2 was higher in the presence of iron deposits in stromal 
inflammatory cells and its expression in epithelial cells was also associated with the FPN 1 
expression in lymphocytes. Concerning clinico-pathological parameters, epithelial CCL2 
expression was statistically associated with the estrogen-receptor negative status.  
 In conclusion, this study further supports the notion that stromal inflammatory cells 
display a deregulation of iron homeostasis, possibly favoring the supply of iron to actively 
proliferating breast tumor cells. Moreover, associations found between the epithelial 
expression of CCL2, infiltration of CCL2-positive macrophages and total macrophage 
infiltration suggest the existence of a paracrine signaling pathway where CCL2, whose 
expression may be putatively enhanced by increased iron deposition in stromal 
inflammatory cells, contributes not only to increased macrophage infiltration into the tumor 
microenvironment, but may also play an indirect role in regulating tumor iron nutrition and 
progression.  
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RESUMO 
 
O carcinoma da mama é a neoplasia mais frequente na população feminina a nível 
mundial, sendo responsável por 25% de todas as neoplasias registadas no ano de 2012.  
O ferro é um microelemento essencial e fundamental para uma variedade de 
processos biológicos e celulares. No entanto, este metal é considerado potencialmente 
carcinogénico, por participar em diversos processos, tais como a formação de radicais 
hidroxilo, supressão da resposta imunitária do hospedeiro ou por ser um nutriente limitante 
para as células tumorais em proliferação. Evidências epidemiológicas, experimentais e 
clínicas suportam a hipótese de que o ferro está associado à iniciação, comportamento e 
progressão do carcinoma da mama. Resultados de diversos estudos indicam que as 
células neoplásicas se apresentam como deficientes em ferro e são capazes de desregular 
os mecanismos de homeostasia deste metal.  
Diversos estudos demonstraram que as células do microambiente tumoral têm uma 
função relevante na tumorigénese e que as interações recíprocas que se estabelecem 
entre as células neoplásicas e do estroma regulam e potenciam a progressão tumoral. O 
recrutamento de leucócitos para o microambiente tumoral envolve a participação de 
citoquinas quimiotáticas. O CCL2 (chemokine [(C-C motif)] ligand 2) é uma das quimiocinas 
mais estudadas no contexto da progressão tumoral, especialmente no carcinoma da 
mama, estando a sua expressão associada com progressão tumoral e mau prognóstico.  
 O principal objetivo deste trabalho foi perceber se a expressão de CCL2, no modelo 
de carcinoma da mama, está relacionada com o status de ferro no tecido. Mais 
especificamente, neste estudo foi avaliada a deposição de ferro no tecido mamário e a 
expressão de CCL2 nas células epiteliais e inflamatórias do estroma. Foram testadas 
associações entre a expressão de CCL2, perfis estabelecidos de (des)regulação de ferro 
e a presença de variantes do gene HFE e a expressão de CCL2 foi correlacionada com 
variáveis clínico-patológicas.  
 Para estudar estas questões, várias técnicas foram realizadas. Os depósitos de 
hemosiderina em amostras normais e de carcinomas, em células epiteliais e inflamatórias 
do estroma, foram identificados usando a técnica de DAB-enhanced Perls’. A expressão 
de CCL2 nas células epiteliais e nos macrófagos foi avaliada através de técnicas de 
imunohistoquímica; a mesma técnica foi utilizada para a determinação da infiltração total 
de macrófagos, recorrendo a um anticorpo anti-CD68. A técnica de PCR-RFLP foi 
executada para a deteção das variantes C282Y e H63D do gene HFE.  
 Comparando com amostras controlo, uma maior proporção de amostras de 
carcinoma da mama apresentava deposição de ferro nas células epiteliais e inflamatórias 
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do estroma. A presença de depósitos de hemosiderina nos macrófagos e/ou linfócitos 
estava significativamente associada com o grau de malignidade. Não foi encontrada uma 
associação estatisticamente significativa entre a expressão de CCL2 nas células epiteliais 
e infiltração total de macrófagos, mas esta estava significativamente associada à infiltração 
de macrófagos CCL2-positivos. Os resultados obtidos indicam ainda que a expressão de 
ferroportina 1 (FPN 1) em macrófagos e linfócitos era superior em amostras de carcinoma, 
comparando com amostras normais. Mais ainda, a expressão mediana de CCL2 era 
superior na presença de depósitos de ferro nas células inflamatórias do estroma, e a sua 
expressão nas células epiteliais estava também associada com a expressão de FPN 1 nos 
linfócitos. No que diz respeito às variáveis clínico-patológicas, a expressão de CCL2 nas 
células epiteliais estava associada à negatividade do recetor de estrogénios.  
 Concluindo, este estudo demonstra que as células inflamatórias do estroma 
também apresentam desregulação dos mecanismos de controlo homeostático do ferro, 
possivelmente favorecendo o fornecimento deste metal a células neoplásicas em constante 
proliferação. Este estudo reporta associações entre a expressão de CCL2 em células 
epiteliais, a infiltração de macrófagos CCL2-positivos e a infiltração total de macrófagos, 
sugerindo a existência de uma via de sinalização parácrina onde a quimiocina CCL2, cuja 
expressão pode ser possivelmente aumentada pela presença de depósitos de 
hemosiderina em células inflamatórias do estroma, não só contribui para o aumento da 
infiltração de macrófagos no microambiente tumoral, mas poderá também ter uma função 
indireta na nutrição tumoral, através da regulação do fornecimento de ferro no tecido. 
  
 
  
  
xiii 
 
TABLE OF CONTENTS 
 
AGRADECIMENTOS .............................................................................................................. VII 
ABSTRACT .............................................................................................................................. IX 
RESUMO .................................................................................................................................. XI 
TABLE OF CONTENTS ......................................................................................................... XIII 
FIGURE INDEX ...................................................................................................................... XV 
TABLE INDEX ....................................................................................................................... XIX 
SUPPLEMENTARY MATERIAL ............................................................................................ XXI 
ABBREVIATIONS LIST ........................................................................................................ XXV 
 
INTRODUCTION ................................................................................................................... - 1 - 
1. BREAST ............................................................................................................................ - 3 - 
1.1 Breast anatomy and histology.................................................................................... - 3 - 
2. BREAST CANCER ............................................................................................................ - 4 - 
2.1 Epidemiology.............................................................................................................. - 4 - 
 2.1.1 Cancer............................................................................................................... - 4 - 
2.2 Histological classification ............................................................................................... - 5 - 
3. IRON METABOLISM ......................................................................................................... - 8 - 
3.1 Role of iron ................................................................................................................. - 8 - 
3.2 Systemic iron regulation ............................................................................................... - 10 - 
3.3 Cellular iron regulation ................................................................................................. - 12 - 
3.4 Iron (de)regulation in neoplastic cells .......................................................................... - 13 - 
3.5 Iron (de)regulation in breast cancer cells ..................................................................... - 14 - 
4. TUMOR MICROENVIRONMENT.................................................................................... - 18 - 
4.1 Importance of the tumor microenvironment ................................................................. - 18 - 
4.2 The role of macrophages ............................................................................................. - 18 - 
4.3 The tumor-associated macrophages’ functions ........................................................... - 20 - 
5. CCL2 ............................................................................................................................... - 22 - 
5.1 CCL2 secretion ............................................................................................................. - 22 - 
5.2 CCL2 expression in breast cancer ............................................................................... - 23 - 
5.3 CCL2 and iron .............................................................................................................. - 24 - 
 
AIMS .................................................................................................................................... - 25 - 
 
MATERIALS AND METHODS ............................................................................................ - 30 - 
1. Breast Cancer Tissue Samples ...................................................................................... - 31 - 
2. Tissue microarray construction ...................................................................................... - 31 - 
3. Heamatoxylin-eosin (H&E) staining ............................................................................... - 33 - 
4. Perls’ Prussian Blue staining .......................................................................................... - 33 - 
5. DAB-enhanced Perls’ technique .................................................................................... - 34 - 
6. Immunohistochemistry ................................................................................................... - 35 - 
7. CCL2 scoring .................................................................................................................. - 44 - 
8. Macrophage counting ..................................................................................................... - 45 - 
9. DNA extraction ............................................................................................................... - 46 - 
10. Statistical analysis ........................................................................................................ - 51 - 
 
RESULTS ............................................................................................................................ - 33 - 
1. DESCRIPTIVE STATISTICS ........................................................................................... - 55 - 
2. DAB-ENHANCED PERLS’ STAINING ............................................................................ - 56 - 
3. IMMUNOHISTOCHEMISTRY ......................................................................................... - 59 - 
3.1 CCL2 expression .......................................................................................................... - 59 - 
xiv 
 
 3.1.1 CCL2 expression in epithelial cells ................................................................. - 59 - 
 3.1.2 CCL2 expression in macrophages .................................................................. - 61 - 
3.3 CD68 expression .......................................................................................................... - 64 - 
3.4 Ferroportin 1 expression .............................................................................................. - 67 - 
 3.4.1 Ferroportin 1 expression in macrophages ...................................................... - 67 - 
 3.4.2 Ferroportin 1 expression in lymphocytes ........................................................ - 69 - 
4. STATISTICAL ANALYSIS ............................................................................................... - 72 - 
4.1 CCL2 expression and macrophage infiltration ............................................................. - 72 - 
4.2 Epithelial CCL2 expression and iron deposition .......................................................... - 72 - 
4.3 Epithelial CCL2 expression and ferroportin 1 expression ............................................ - 74 - 
5. HFE VARIANTS .............................................................................................................. - 76 - 
5.1 C282Y variant ............................................................................................................... - 76 - 
5.2 H63D variant ................................................................................................................ - 77 - 
 5.2.1 H63D variant and tissue iron status ................................................................ - 78 - 
 5.2.2 H63D variant and CCL2 expression ............................................................... - 78 - 
6. CLINICO-PATHOLOGICAL ASSOCIATIONS ................................................................ - 79 - 
6.1 Pathological and clinical parameters............................................................................ - 79 - 
6.2 Epithelial CCL2 expression .......................................................................................... - 79 - 
6.3 Infiltration of CCL2-positive macrophages ................................................................... - 80 - 
6.4 Total macrophage infiltration ........................................................................................ - 80 - 
 
DISCUSSION ...................................................................................................................... - 58 - 
 
CONCLUSIONS .................................................................................................................. - 88 - 
 
BIBLIOGRAPHY .................................................................................................................. - 96 - 
 
SUPPLEMENTARY MATERIAL .......................................................................................... - 95 - 
 
 
 
 
xv 
 
FIGURE INDEX 
 
Figure 1: Schematic diagram of the breast. Adapted from (3)……………………….………..3 
Figure 2: Histopathological-based model of human ductal breast cancer progression, 
demonstrating the transition from benign proliferative changes, which may evolve to atypical 
or typical hyperplasia and in situ carcinoma, culminating in an invasive lesion. Adapted from 
(14)……………………………………………………………………………………………….....5 
Figure 3: Regulation of Systemic Iron Homeostasis through hepcidin. Iron overload leads 
to hepcidin secretion by hepatocytes with consequent iron retention in enterocytes, 
hepatocytes and macrophages of the RES. Conversely, in situations of iron deficiency, 
hepcidin production is suppressed and iron actively exported. Adapted from (63)…..……..12 
Figure 4: Representation of TMA construction. (A) Cores previously selected in the 
corresponding slide stained with H&E can be extracted from the original paraffin block with 
the help of an extractor. (B) Extractor allows the section of regions with 2.0 mm and placing 
in the recipient block. (C) Tissue samples is placed in the paraffin block built in the TMA 
builder, according to a designed map. Image adapted from (176)………………………...…32 
Figure 5: DAB-enhanced Perls’ staining of breast tumors, n epithelial (left) and stromal 
inflammatory cells (right). Original magnification of 400X (left) and 200X (right)……………56 
Figure 6: Iron deposition in epithelial (blue) and in stromal inflammatory cells (green) in 
pure lesions. Chi-square test for iron deposition in stromal inflammatory cells: between 
normal and pure DCIS p=0.011; between normal and pure IDC p=0.001 (*p< 0.05, **p< 
0.01, ***p< 0.001). Abbreviations: EC, epithelial cells; SIC, stromal inflammatory cells; 
DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma……………………..………57 
Figure 7: Iron deposition in epithelial (blue) and in stromal inflammatory cells (green) in 
histologically “normal” adjacent tissue. Chi-square test for iron deposition in stromal 
inflammatory cells: p=0.037; between normal and normal adjacent to IDC lesions p=0.011 
(*p< 0.05, **p< 0.01, ***p< 0.001).  Abbreviations: EC, epithelial cells; SIC, stromal 
inflammatory cells; DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma……….58 
Figure 8: Representative images of epithelial CCL2 immunostaining in normal, DCIS 
(ductal carcinoma in situ) and IDC (invasive ductal carcinoma) cases. Original magnification 
400X……………………………………………………………………………………………….59 
Figure 9: Median CCL2 expression in normal, pure ductal carcinoma in situ (DCIS) and 
invasive ductal carcinoma (IDC) lesions. Dunn-Bonferroni test: between normal and pure 
IDC p=0.017 (*p< 0.05, **p< 0.01, ***p< 0.001, versus precedent group). Error bars: 95% 
CI. Abbreviations: DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma.……….60 
Figure 10: Median epithelial CCL2 expression in histologically normal tissue, adjacent to 
carcinoma lesions. Error bars: 95% CI. Abbreviations: DCIS, ductal carcinoma in situ; IDC, 
invasive ductal carcinoma.……………………………………………………………………....61 
Figure 11: Section of a DCIS (ductal carcinoma in situ) lesion, immunostained for CD68 
(on the left) and CCL2 (on the right). A few examples of CCL2-positive macrophages are 
shown and marked with an *. Original magnification 400X........……………………………..62 
Figure 12: Infiltration of CCL2-positive macrophages in Pure Lesions. Dunn-Bonferroni test: 
between normal and pure DCIS p<0.001; between normal and pure IDC p=0.001 (*p< 0.05, 
xvi 
 
**p< 0.01, ***p< 0.001, versus precedent group). Error bars: 95% CI. Abbreviations: DCIS, 
ductal carcinoma in situ; IDC, invasive ductal carcinoma……………...……………...……...62 
Figure 13: Infiltration of CCL2-positive macrophages in normal adjacent tissue. Error bars: 
95% CI. Abbreviations: DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma….63 
Figure 14: Representative images of CD68 immunostaining in normal, DCIS (ductal 
carcinoma in situ) and IDC (invasive ductal carcinoma) cases. Original magnification 200X. 
...........................................................................................................................................64 
Figure 15: Total macrophage infiltration in pure lesions. Dunn-Bonferroni test: between 
normal and pure DCIS p=0.003 and normal and pure IDC p<0.001 (*p< 0.05, **p< 0.01, 
***p< 0.001, versus precedent group). Error bars: 95% CI. Abbreviations: DCIS, ductal 
carcinoma in situ; IDC, invasive ductal carcinoma……..………………………...……………65 
Figure 16: Total macrophage infiltration in normal tissue adjacent to carcinoma lesions. 
Error bars: 95% CI. Abbreviations: DCIS, ductal carcinoma in situ; IDC, invasive ductal 
carcinoma…..……………………………………………………………………….…………….66 
Figure 17: Section of a DCIS (ductal carcinoma in situ) lesion, immunostained for 
ferroportin 1. Stromal inflammatory cells present an evident immunostaining, particularly in 
the cytoplasm. Original magnification 400X…………………………………………...……….67 
Figure 18: Ferroportin 1 expression in macrophages, in pure lesions. Dunn-Bonferroni test: 
between normal and pure DCIS p=0.001; pure DCIS and pure IDC p<0.001 (*p< 0.05, **p< 
0.01, ***p< 0.001, versus precedent group). Error bars: 95% CI. Abbreviations: DCIS, ductal 
carcinoma in situ; IDC, invasive ductal carcinoma…………………….……….……………...68 
Figure 19: Ferroportin 1 expression in macrophages, in histologically “normal” tissue 
adjacent to carcinoma lesions. Dunn-Bonferroni test: between normal and “normal” tissue 
adjacent to DCIS lesions p=0.007 (*p< 0.05, **p< 0.01, ***p< 0.001, versus precedent 
group). Error bars: 95% CI. Abbreviations: DCIS, ductal carcinoma in situ; IDC, invasive 
ductal carcinoma…………….……………………………………………………………..…….69 
Figure 20: Ferroportin 1 expression in lymphocytes, in pure lesions. Dunn-Bonferroni test: 
between normal pure IDC p=0.016 (*p< 0.05, **p< 0.01, ***p< 0.001, versus precedent 
group). Error bars: 95% CI. Abbreviations: DCIS, ductal carcinoma in situ; IDC, invasive 
ductal carcinoma………………………………………………………………………………….70 
Figure 21: Ferroportin 1 expression in lymphocytes, in histologically “normal” tissue 
adjacent to carcinoma lesions. Error bars: 95% CI. Abbreviations: DCIS, ductal carcinoma 
in situ; IDC, invasive ductal carcinoma.…………………………………………………………71 
Figure 22: Correlation graph between infiltration of CCL2-positive macrophages and total 
macrophage infiltration. Linear r-squared value=0.253.………………………………………72 
Figure 23:  Median CCL2 expression in epithelial cells according to tissue iron deposition 
status in epithelial cells (p>0.05). Error bars: 95% CI. ………………………………...…….73 
Figure 24:  Median CCL2 expression in epithelial cells according to tissue iron deposition 
status in stromal inflammatory cells. Error bars: 95% CI.……………………………………74 
Figure 25:  Correlation between CCL2 expression in epithelial cells and ferroportin 1 
expression in lymphocytes (p=0.001). Linear r-squared value=0.200.……………………...75 
Figure 26: Percentage of samples genotyped as CC or CY by samples diagnosis………..76 
xvii 
 
Figure 27: Percentage of samples genotyped as HH, HD or DD by samples 
diagnosis…………………………………………………………………….…………………….77 
Figure 28:  Median CCL2 expression in epithelial cells according to the genotype in 
epithelial cells. Mann Whitney’s U test: p-value>0.05. Error bars: 95% CI………………….78 
Figure 29: Median CCL2 expression in epithelial cells in samples ER-negative and ER-
positive. Mann-whitney’s U test: p=0.021. Error bars: 95% CI. Abbreviations: DCIS, Ductal 
carcinoma in situ; ER, estrogen receptor. …………………………………………………...…80 
Figure 30: Proposed mechanism for the CCL2-induced pathway: CCL2 (green circles), 
produced by breast tumor cells, attract circulating CCR2-positive cells, such as 
macrophages and lymphocytes, which are iron-loaded. When these stromal inflammatory 
cells arrive to the tumor microenvironment, FPN 1 expression is upregulated, partially by 
the expression of CCL2, and iron (Fe) is supplied for proliferating epithelial cells. Iron 
supplied by macrophages and lymphocytes leads to increased proliferation and CCL2 
secretion by tumor cells, triggering the paracrine signalling pathway, between tumor and 
immune cells. Macrophages are also accountable for the production of CCL2, resulting in 
increased leukocyte infiltration and increased iron supply for proliferating neoplastic cells. 
……………………………………………………………………………………….…………….92 
 
 
 
 
 
xix 
 
TABLE INDEX 
 
Table 1: Representative images of CCL2 immunostaining performed on negative and 
positive controls for protocol optimization. Different dilutions were tested and antigen 
retrieval was performed using Dako Target Retrieval Solution.……..…………..…………...31 
Table 2: Representative images of CCL2 immunohistochemistry performed on breast 
cancer tissue. Different dilutions were tested and antigen retrieval was performed using 
Dako Target Retrieval Solution…………………………………………………..…………...…32 
Table 3: Representative images of CCL2 immunohistochemistry performed on positive 
controls. Same dilution was tested (1:100), with different antigen retrieval methods………34 
Table 4: Representative images of CCL2 immunohistochemistry performed on breast 
cancer tissue. Same dilution was tested (1:100), with different antigen retrieval 
methods……………………………………………………………………………….…………..35 
Table 5: Representative images of CCl2 immunohistochemistry performed on lymph node 
(positive control) and breast cancer tissue. Antigen retrieval with citrate buffer and revelation 
with the ABC method were performed………………………………………………...………..36 
Table 6:  Description of the Multiplex PCR Components used for amplification of the C282Y 
and H63D variants of the HFE gene…………………………………………….…………...….43 
Table 7:  Tissue sample and core frequencies……………………………...…………………48 
 
 
 
xxi 
 
SUPPLEMENTARY MATERIAL 
 
Table 8: Frequencies and percentages of lesions considered in this study……………..109 
Table 9: Table demonstrating the p-value obtained from the Kolmogorov-Smirnov test, 
performed in order to assess the distribution and normality of data………………………109 
Table 10: Contingency table demonstrating the frequencies and percentages of normal, 
pure DCIS and pure IDC samples presenting iron deposition in epithelial cells…………...110 
Table 11: Contingency table demonstrating the frequency and percentage of normal, pure 
DCIS and pure IDC samples with iron deposition in stromal inflammatory cells…………..111 
Table 12: Pearson’s Chi-square test: differences in iron deposition in epithelial cells 
between sub-groups of lesions………………………………………………………………...111 
Table 13: Pearson’s Chi-square test: differences in iron deposition in stromal inflammatory 
cells between sub-groups of lesions…………………………………………………………..112 
Table 14: Pearson’s Chi-square test: differences in iron deposition in stromal inflammatory 
cells between normal and pure DCIS lesions…………………………………………………112 
Table 15: Pearson’s Chi-square test: differences in iron deposition in stromal inflammatory 
cells between normal and pure IDC lesions…………………………………………………..112 
Table 16: Pearson’s Chi-square test: differences in iron deposition in stromal inflammatory 
cells between pure DCIS and pure IDC lesions………………………………………………113 
Table 17: Contingency table demonstrating the frequency and percentage of normal 
samples and samples constituted by histologically “normal” tissue adjacent to DCIS or IDC 
presenting iron deposition in epithelial cells…………………………………………………..114 
Table 18: Contingency table demonstrating the frequency and percentage of normal 
samples and samples constituted by histologically “normal” tissue adjacent to DCIS or IDC 
presenting iron deposition in stromal inflammatory cells…………………………………….115 
Table 19: Pearson’s Chi-square test: differences in iron deposition in epithelial cells 
between sub-groups of lesions………………………………………………………………...116 
Table 20: Pearson’s Chi-square test: differences in iron deposition in stromal inflammatory 
cells between sub-groups of lesions…………………………………………………………..116 
Table 21: Pearson’s Chi-square test: differences in iron deposition in stromal inflammatory 
cells between normal and “normal” tissue adjacent to DCIS lesions……………………….116 
Table 22: Pearson’s Chi-square test: differences in iron deposition in stromal inflammatory 
cells between normal and “normal” tissue adjacent to IDC lesions…………………………117 
Table 23: Pearson’s Chi-square test: differences in iron deposition in stromal inflammatory 
cells between “normal” tissue adjacent to DCIS lesions and normal tissue adjacent to IDC 
lesions……………………………………………………………………………………………117 
Table 24:  Spearman’s rank correlation test: Epithelial CCL2 expression…………………118 
 
xxii 
 
Table 25: Kruskal-Wallis test: differences in epithelial CCL2 expression between sub-
groups of pure lesions…………………………………………………………………………..118 
Table 26: Dunn-Bonferroni test: differences in epithelial CCL2 expression between sub-
groups of pure lesions…………………………………………………………………………..119 
Table 27: Kruskal-Wallis test: differences in epithelial CCL2 expression between normal 
tissue from reduction mammoplasties and histologically “normal” tissue adjacent to 
carcinomas………………………………………………………………………………………119 
Table 28: Spearman’s rank correlation test: infiltration of CCL2-positive macrophages…120 
Table 29: Kruskal-Wallis test: differences in the infiltration of CCL2-positive macrophages 
between pure sub-groups of lesions…………………………………………………………..120 
Table 30: Dunn-Bonferroni test: differences in the infiltration of CCL2-positive macrophages 
between sub-groups of pure lesions…………………………………………………………..121 
Table 31: Kruskal-Wallis test: differences in the infiltration of CCL2-positive macrophages 
between normal tissue from reduction mammoplasties and histologically “normal” tissue 
adjacent to carcinomas…………………………………………………………………………121 
 
Table 32: Spearman’s rank correlation test: total macrophage infiltration.........................122 
Table 33: Kruskal-Wallis test: differences in total macrophage infiltration between sub-
groups of pure lesions…………………………………………………………………………..122 
Table 34: Dunn-Bonferroni test: differences in the total macrophage infiltration between 
sub-groups of pure lesions……………………………………………………………………..123 
Table 35: Kruskal-Wallis test: differences in the total macrophage infiltration between 
normal tissue from reduction mammoplasties and histologically “normal” tissue adjacent to 
carcinomas………………………………………………………………………………………123 
Table 36:  Spearman’s rank correlation test: epithelial CCL2 expression and total 
macrophage infiltration…………………………………………………………………………124 
Table 37:  Spearman’s rank correlation test: epithelial CCL2 expression and infiltration of 
CCL2-positive macrophages…………………………………………………………………..124 
Table 38:  Spearman’s rank correlation test: infiltration of CCL2-positive macrophages and 
total macrophage infiltration……………………………………………………………………124 
Table 39:  Mann-Whitney test: differences in epithelial CCL2 expression, regarding the 
presence of hemosiderin deposition in epithelial cells……………………………………….125 
Table 40:  Mann-Whitney test: differences in epithelial CCL2 expression, regarding the 
presence of hemosiderin deposition in stromal inflammatory cells…………………………125 
Table 41:  Mann-Whitney test: differences in ferroportin 1 expression in lymphocytes, 
regarding the presence of hemosiderin deposition in epithelial cells……………………….125 
Table 42:  Mann-Whitney test: differences in ferroportin 1 expression in lymphocytes, 
regarding the presence of hemosiderin deposition in stromal inflammatory cells…………126 
Table 43:  Mann-Whitney test: differences in ferroportin 1 expression in macrophages, 
regarding the presence of hemosiderin deposition in epithelial cells……………………..126 
xxiii 
 
Table 44:  Mann-Whitney test: differences in ferroportin 1 expression in macrophages, 
regarding the presence of hemosiderin deposition in stromal inflammatory cells…………126 
Table 45:  Pearson’s Chi-square test: differences in the distribution of the C282Y variants 
between sub-groups of lesions………………………………………………………………...127 
Table 46:  Pearson’s Chi-square test: analyzing differences in the distribution of the H63D 
variants between sub-groups of lesions………………………………………………………127 
Table 47:  Pearson’s Chi-square test: differences in the distribution of the H63D variants 
with the presence of iron deposition in epithelial cells……………………………………….127 
Table 48:  Pearson’s Chi-square test: differences in the distribution of the H63D variants 
with the presence of iron deposition in stromal inflammatory cells…………………………128 
Table 49:  Mann-Whitney test: differences in the median expression of CCL2 between 
H63D variants……………………………………………………………………………………128 
Table 50: Mann-Whitney test: differences in the median expression of CCL2 regarding the 
ER-status, in DCIS samples……………………………………………………………………128 
Table 51: Mann-Whitney test: differences in the median expression of CCL2 regarding the 
ER-status, in IDC samples……………………………………………………………………..129 
Table 52: Spearman’s rank correlation test: CCL2 expression and leukocyte count……..129 
Table 53: Mann-Whitney test: differences in the median expression of CCL2 regarding the 
PR-status, in DCIS samples……………………………………………………………………129 
Table 54: Mann-Whitney test: differences in the median expression of CCL2 regarding the 
PR-status, in IDC samples……………………………………………………………………..130 
Table 55: Mann-Whitney test: differences in the median expression of CCL2 regarding the 
HER-2 status…………………………………………………………………………………….130 
Table 56: Mann-Whitney test: differences in the median expression of CCL2 regarding 
lymph node involvement………………………………………………………………………..130
 
 
 
 
  
 
 
ABBREVIATIONS LIST 
 
µL – Microliter 
µM – Micromolar 
ABC – Avidin-Biotin Complex 
APES - 3-aminopropyltriethoxysilane 
BCa – Breast cancer 
CCL2 - Chemokine (C-C motif) ligand 
2 
CCR2 – C-C chemokine receptor type 
2 
CD – Cluster of differentiation 
CD1 – Cyclin D1 
cf. - confer 
CI – Confidence Interval 
CSF-1 – Colony stimulating factor 1 
DAB - Diaminobenzidine 
DCIS – Ductal carcinoma in situ  
DcytB - Duodenal cytochrome b 
DFO - Deferoxamine  
DMBA - 7,12-
Dimethylbenz[a]anthracene 
DMT1 - Divalent metal transporter 1 
DNA – Deoxyribonucleic Acid 
EC – Epithelial cells 
EDTA - Ethylenediaminetetraacetic 
acid 
EGF – Endothelial growth factor 
ER – Estrogen receptor 
FAC – Ammonium ferric citrate 
Fe/S – Iron-sulfur 
FFPE – Formalin fixed paraffin-
embedded 
FPN1 – Ferroportin 1  
H&E - Heamotoxylin-eosin  
H2O2 – Hydrogen Peroxide 
HCC - Haemofiltrate CC chemokine 
HCP-1 - Heme-carrier protein 1  
HER-2 – Human epidermal growth 
factor 2 
HH - Hereditary hemochromatosis 
HIF – Hypoxia inducible factor 
HPF – High power field 
HRE – Hypoxia responsive element 
IDC – Invasive ductal carcinoma 
IFN-γ – Interferon-gamma 
IL - Interleukin 
IRE – Iron-regulatory element 
IRP – Iron-regulatory protein 
LIP – Labile iron pool 
LPS - Lipopolysaccharide 
Ly – Lymphocyte 
M0 – Macrophage 
MCP-1 – Monocyte chemoattractant 
chemokine 1 
MHC – Major histocompatibility 
complex 
MMP – Metalloproteinase 
mRNA – Messenger RNA  
NaCl – Sodium chloride 
ng – Nanogram 
NK – Natural killer 
ºC – Celsius degree 
PCR – Polymerase chain reaction 
PCR-RFLP – PCR – Restriction 
Fragment length polymorphism 
 
 
PR – Progesterone receptor 
RCLB – Red cell lysis buffer 
RES - Reticuloendothelial system 
RNA – Ribonucleic acid 
ROS – Reactive oxygen species 
rpm – Rotations per minute  
RR - Ribonucleotide reductase 
SDS – Sodium dodecyl sulfate 
SEM – Standard error of mean 
SIC – Stromal inflammatory cells 
SNP – Single nucleotide polymorphism 
STEAP3 –Six-transmembrane 
epithelial antigen of the prostate 3 
TAE - Tris-acetate-EDTA 
TAM – Tumor-associated macrophage 
TBS - Tris-buffered saline 
TDLU – Terminal ductal lobular unit 
TE – Tris-EDTA 
TE-2 – Tris-EDTA 2X 
Tf – Transferrin 
TfR1 – Transferrin receptor 1 
TMA – Tissue microarray 
TME – Tumor microenvironment 
UTR – Untranslated region 
V - Volt 
VEGF – Vascular endothelial growth 
factor 
VEGFR – Vascular endothelial growth 
factor receptor 
VHL – Von Hippel Lindau 
WHO – World health organization 
 
 
  
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
  
 
 
  
   - 3 - 
 
1. BREAST 
1.1 Breast anatomy and histology 
  
 The breast is an apocrine modified gland, responsible for the production of milk, 
essential for the nutrition of the newborn. This gland is permanently under hormonal control, 
which regulates its development during puberty and secretory activity during the latter half 
of pregnancy (1).  
 
The mammary gland is localized between the second and sixth ribs in the vertical 
axis and between the sternal border and the mid-axillary line in the horizontal axis. The 
mammary gland develops within the superficial fascia and is maintained in place by the 
Cooper suspensory ligaments (2).  
  
 
 
 
  
 
 
 
Figure 1: Schematic diagram of the breast. Adapted from (3). 
 The adult breast is formed by skin, subcutaneous tissue and breast tissue, which 
comprises the parenchyma and stroma (2). The parenchyma is divided into 15 to 20 
irregular lobes that converge at the nipple in a radial manner, to the lactiferous ducts, which 
are the excretory canals (4). Lobes diverge into a progressive branching system of ducts 
that end in terminal ductal lobular units (TDLU), the smallest functional units of the breast 
(5). These structures are responsible for the production of milk and are also the primary 
origin of most mammary carcinomas (6). 
Stromal and subcutaneous components contain adipose and connective tissue, blood and 
lymphatic vessels and nerves (2). 
 The mammary papilla or nipple is a cylindrical or conical projection from just below 
the center of the anterior surface of the breast (7). 
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2. BREAST CANCER 
2.1  Epidemiology 
 2.1.1 Cancer 
 
The global burden of neoplastic diseases keeps increasing worldwide, reinforcing 
its status as a major health problem. This is mainly due to population growth, together with 
aging, but also improvement of screening and early detection techniques (8). Also 
associated with this increase is the maintenance of cancer-promoting habits, such as 
smoking, alcohol consumption and sedentary lifestyle, particularly in economically 
developing countries (9).  
Cancer is the leading cause of death in economically developed countries and is the 
second cause of death in developing countries, following cardiovascular conditions (10).  
The most frequent cancers worldwide, considering both sexes, are lung, breast and 
colorectal cancer In females, breast cancer is the most frequent (23%), followed by 
colorectal (9.2%) and corpus uteri cancer (9%) (9).   
In Europe, and in Portugal, amongst females, breast cancer is the most frequent 
malignancy (11).  
2.1.2 Breast Cancer 
 
Breast carcinoma is the most common neoplasm affecting women worldwide, 
accounting for 25% of all malignancies diagnosed in 2012 (12). Moreover, it is the fifth cause 
of death from cancer worldwide, taken both sexes into account, comprising 6.4% of the total 
cancer deaths (9).   
In more developed countries, among women, breast cancer is the second cause of 
death (15.4% of total), following lung cancer (19.4%), while in developing countries it is the 
leading cause of death (14.3%) (12).  
In Europe, breast cancer is the most common neoplastic disease, accounting for 
464000 cases (14% of all cancer cases). This malignancy was also the fourth leading cause 
of cancer-related death, with an estimated of 131000 deaths (11).  
In Portugal, is the fifth cause of cancer-related death (6.5%), considering both sexes. 
Among females, is the leading cause of cancer death, comprising 16% of total cancer 
registered in 2012 (13).  
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2.2 Histological classification 
 
 The natural history of mammary carcinomas starts with abnormal benign 
proliferation, which may result in in situ and invasive carcinomas and culminating in 
metastatic disease (14). The “linear” multistep model is universally accepted, which 
suggests a transition from normal epithelial to invasive breast carcinoma via typical and 
atypical hyperplasia and in situ carcinoma, through accumulation of genetic mutations, as 
illustrated in figure 2 (5). 
  
 
Figure 2: Histopathological-based model of human ductal breast cancer progression, 
demonstrating the transition from benign proliferative changes, which may evolve to atypical or 
typical hyperplasia and in situ carcinoma, culminating in an invasive lesion. Adapted from (14). 
 
 Pre-invasive and invasive lesions are divided into 2 general histological categories: 
ductal or lobular subtypes. Data regarding histogenesis of mammary carcinoma has 
demonstrated that most breast cancers, ductal or lobular subtype, arise from TDLUs (15). 
Nowadays, distinction between the 2 subtypes is based upon differences in cell morphology 
(5). 
 
 Malignant tumors may arise from any of the tissues composing the breast. Ductal 
carcinomas are the most frequent, followed by lobular malignancies, both arising from the 
epithelial compartment of the breast. Another histological subtypes, more rare, are listed 
and classified by WHO and can be found in reference (16). 
 
2.2.1 Benign tumors 
 
 The designation of benign tumors comprehends a heterogeneous group of lesions, 
which are normally detected as a palpable mass, a non-palpable abnormality detected on 
breast imaging examination or an incidental microscopic finding (2). Histologically, these 
lesions remain constricted and display no cellular heterogeneity (4).  
   - 6 - 
 
 Dupont and colleagues performed a retrospective study evaluating benign breast 
disease and cancer risk. For this, more than 10000 slides from women diagnosed with 
benign breast lesions were analyzed and, accordingly to stipulated criteria, grouped into 
one of 3 groups: non-proliferative lesions, proliferative lesions without atypia or atypical 
hyperplasias. Women diagnosed with non-proliferative lesions did not have an increased 
risk for subsequent cancer. On the other hand, women diagnosed with proliferative lesions 
without atypia or atypical hyperplasias had an increased risk of subsequent breast cancer, 
compared with non-proliferative diseases (1.9 and 5.3 times, respectively). According to this 
study, the majority of women (70%) who underwent breast biopsy for benign disease were 
not at increased risk for breast cancer (17). 
 2.2.2 Ductal carcinomas in situ 
 
 Ductal carcinomas in situ (DCIS) are the most common type of non-invasive breast 
cancer in women (18). In the past 20 years, incidence of this lesion has increased, mostly 
due to increased detection, through the widespread implementation of radiographic 
screening for invasive carcinoma (19, 20).  
 
 DCIS is defined as the clonal proliferation of neoplastic cells, which remain confined 
to the lumens of the mammary ducts (16). Ducts are surrounded by myoepithelial cells, 
which form an intact basement membrane (20). It is considered to be a precursor lesion, 
associated with an increased risk of subsequent invasive carcinoma (5).    
 DCIS is considered to be a spectrum of disease, ranging from small, low-grade 
lesions, treatable by surgical excision to extensive, high-grade lesions, which require a 
mastectomy for complete eradication (21). At present, there is no universally accepted 
classification system for in situ lesions. To correctly differentiate lesions and consequently 
stratify patients that will most benefit from each treatment, the pathological report must refer 
information regarding tumor size, nuclear grade, architectural patterns, presence of 
necrosis, margin assessment and existence of microcalcifications (22).  
2.2.3 Invasive ductal carcinomas 
  
 Invasive ductal carcinoma (IDC) is the most frequent malignant mammary tumor, 
comprising approximately 75% of mammary carcinomas (4). Classification used is that of 
WHO, which is based particularly on growth patterns and cytologic features of invasive 
tumor cells (16). The principal diagnostic criterion that allows the differentiation of invasive 
from in situ carcinomas is the disruption of the myoepithelial cell layer and basement 
membrane (23). 
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 A vast majority of invasive tumors are associated with an in situ carcinoma (2). The 
prevailing view is that invasive carcinomas derive from the in situ component, based on the 
frequent coexistence of the 2 lesions, but also on the histological resemblances between 
both components within the same lesion (24). Moreover, coexisting in situ and invasive 
carcinomas often share the same genetic alterations and immunophenotypes (25). 
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 3. IRON METABOLISM 
3.1 Role of iron  
 
 Iron is an essential microelement, vital for a variety of biological and cellular 
processes, such as DNA synthesis, oxygen transport and cell cycle regulation (26, 27). Iron 
is pivotal for the functioning of numerous enzymes and proteins, such as ribonucleotide 
reductase (28), hemoglobin (29), cyclins (30) and p53 (31). Iron depletion leads to inhibition 
of cell proliferation, cell cycle arrest at G1/S phase transition and apoptosis (26). 
 
3.1.1 Iron and DNA synthesis  
 
Ribonucleotide reductase (RR) is a rate-limiting enzyme, formed by two dimers, 
responsible for the conversion of ribonucleotides into deoxyribonucleotides (26). Protein 
R1, or α2 dimer, contains the active and binding site for the allosteric effectors, and protein 
R2, also called β2 dimer, is composed by a binuclear ferric iron center, responsible for the 
generation and maintenance of a tyrosyl radical, necessary for catalysis (28, 32, 33). Iron 
is fundamental for the enzyme activity, because the free radical needs its constant supply 
to regenerate (28). 
  
Studies performed by Lederman and colleagues, in which they supplied 
deferoxamine (DFO), an iron chelator, to human B lymphocyte and T lymphocyte cell  lines, 
led to a loss of function of RR, resulting in cell cycle arrest and inhibition of proliferation (34). 
Subsequent studies performed by Nyholm and his group led to the conclusion that some 
iron chelators inhibited RR activity, in a mammary cell line, by removing all soluble iron from 
the medium and preventing the regeneration of the iron center in the apo-R2 subunit (35). 
Further studies confirmed these reports (36). 
 
3.1.2 Iron in the cell cycle 
 
Highest demands for iron occur during late G1 phase and throughout S phase of the 
cell cycle (37). Although this happens mostly because of the increasing activity of RR, iron 
also plays a role in regulating cyclins (30).  
Iron depletion decreases the protein levels of cyclin A, B and D, and increases the 
levels of cyclin E (38). 
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Cyclin D1 (CD1) is the most important regulator of cell progression to replication 
phase and is also considered an oncogene, because its overexpression releases cells from 
tight regulation (39).   
 CD1 is decreased by iron depletion, leading to G1/S arrest and impaired cellular 
proliferation. Thereby targeting its degradation may represent a new chemotherapeutic 
approach (40). 
 
3.1.3 Iron in oxygen transport 
 
Hemoglobin is an oxygen-carrier metalloprotein present in erythrocytes (41). This 
protein is formed by two polypeptide chains, α and β, each bound to a heme group. Each 
heme group is composed by a ferrous atom and a porphyrin ring and functions as a 
reversible carrier, supplying oxygen into tissues and transporting carbon dioxide back to the 
lungs (29, 41, 42).  
In erythroid cells, heme biosynthesis is dependent on the availability of iron in the 
form of iron-sulfer (Fe/S) clusters. Plus, the enzyme ferrochelatase, which catalyzes the 
insertion of iron into protoporphyrin IX, needs iron for the efficient formation of heme (29). 
Iron deficiency anemia leads to impaired heme biosynthesis and reduced hemoglobin 
synthesis, resulting in abnormally small and fragile red blood cells. The outcome is the 
reduction in the capacity of the erythrocytes to transport oxygen into the body cells and 
tissues (43). 
 
 
As described above iron is fundamental for the correct function of a variety of cellular 
processes. However, iron is also associated with toxicity. Through the Fenton and Haber-
Weiss reactions, ferrous iron, in the presence of hydrogen peroxidase, is able to donate an 
electron to produce hydroxyl radicals, a type of reactive oxygen species (ROS). This is 
causative of DNA base modifications and strand breaks, causing oxidative stress. 
Moreover, iron deficiency or overload is responsible for a multitude of diseases (44).  
Due to its potential toxicity and pathogenicity, iron is tightly regulated at the systemic 
and cellular level and this is accomplished by a synchronized control of iron uptake, storage 
and export (45). 
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3.2 Systemic iron regulation 
 
In mammals a controlled physiological mechanism for iron excretion is absent, so 
absorption by enterocytes is highly regulated in order to maintain iron homeostasis (46).  
 About 1-2 mg of iron is absorbed per day from diet and it can be obtained in an 
inorganic non-heme or organic heme formulation. Non-heme iron, mostly present in 
vegetables, accounts for 90% of dietary iron, but only approximately 10% of it is absorbed 
in the intestine; on the other hand, heme iron, present in meat, is more efficiently absorbed 
(47). 
 
 Iron is absorbed accordingly to the organism demands, in order to replace losses in 
urine, sweat and from desquamation of intestinal cells (45). In healthy individuals, intestinal 
iron absorption is regulated by body iron stores, hypoxia, inflammation and erythropoietic 
activity (48). 
 
3.2.1 Intestinal Iron Absorption 
 
  Enterocytes lining the absorptive villi, close to the gastroduodenal junction, are 
responsible for iron absorption. Mechanisms by which heme iron is absorbed are dependent 
on the heme-carrier protein 1 (HCP-1), which also transports folate (49). Dietary non-heme 
iron is absorbed at the apical border, through DMT1 (divalent metal transporter 1) and after 
reduction by membrane ferrireductases, such as DcytB (duodenal cytochrome B), it enters 
a common pathway with dietary heme iron (44, 50).  
 Iron inside the enterocyte may remain in the form of ferritin, until these cells reach 
senescence and slough off (44). Iron can also be exported into blood circulation via the only 
known exporter identified to date, ferroportin 1 (FPN1), localized on the basolateral 
membrane (51). The egress of iron from the enterocyte is dependent on its oxidation, by 
the membrane bound multicopper oxidase hephaestin, which enables iron binding to plasm 
transferrin (Tf) (52).  
 
3.2.2 Iron distribution and utilization 
 
 The major depots of iron are circulating hemoglobin and myoglobin, which contain 
about 85% of the total body iron content (53, 54). About 20% of the remaining body iron is 
stored in hepatocytes and in reticuloendothelial macrophages (44). Although only 1% of 
body iron is stored in transferrin, it is the most important dynamic iron pool, with the highest 
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turnover rate (55). About 80% of iron bound to transferrin is delivered to the bone marrow 
for the development of new erythrocytes (56).  
 In order to encounter large iron needs for erythropoiesis, the Reticuloendothelial 
System (RES), composed of monocytes and macrophages, recycles iron from senescent 
red cells by a process named erythrophagocytosis (57). Iron can be stored within the 
macrophage or loaded onto transferrin for reuse, depending on systemic iron requirements 
(58). 
3.2.3 Regulation of systemic iron balance 
 
 Systemic iron homeostasis is regulated by hepcidin, a hormone secreted mainly by 
hepatocytes (59). Hepcidin production is regulated by iron levels: when iron is abundant, 
more hepcidin is produced, therefore limiting iron absorption and release from body stores; 
when iron is deficient, hepatocytes produce less or no hepcidin, allowing iron to be absorbed 
and enter the plasma. So, hepcidin is a negative key regulator of iron metabolism at the 
systemic level, controlling absorption, release from macrophages or mobilization from 
depots (60).  
Hepcidin is also regulated by erythropoietic demands. Through a not completely clarified 
mechanism, hepcidin production is suppressed in times of active erythropoiesis, increasing 
iron availability for hemoglobin synthesis (60). Erythroferrone was recently identified as the 
putatively mediator of hepcidin suppression during active erythropoiesis (61). 
 
  Hepcidin regulates iron efflux through binding to ferroportin 1, which leads to its 
internalization and degradation, resulting in cellular iron retention in hepatocytes, 
enterocytes and macrophages (62). 
 
 Schematic representation of iron regulation via hepcidin is illustrated in figure 3.  
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Figure 3: Regulation of Systemic Iron Homeostasis through hepcidin. Iron overload leads to 
hepcidin secretion by hepatocytes with consequent iron retention in enterocytes, hepatocytes 
and macrophages of the RES. Conversely, in situations of iron deficiency, hepcidin production 
is suppressed and iron actively exported.  Adapted from (63). 
 
3.3 Cellular iron regulation 
 
 In order to prevent cellular toxicity and ensure iron availability for essential molecular 
processes, coordination of iron uptake, utilization and storage at the cell level are also tightly 
regulated (63).  
 
 Iron in the ferric form (Fe(III)), bound to transferrin, binds to the transferrin receptor 
1 (TfR1) and this complex is internalized by clathrin-dependent endocytosis. Acidification of 
the endosome leads to iron release from the complex, and transferrin plus TfR1 are recycled 
back into the cell surface. In the endosome, the ferrireductase STEAP3 reduces iron into a 
Fe(II) form, which allows its transport into the cytosol by DMT1. Iron can then be stored into 
ferritin or enter the intracellular labile iron pool (LIP) (63). LIP is considered to be the 
transitional step between iron released from the endosomal compartment and storage in 
ferritin or for use in cellular processes. In physiological conditions, this iron pool is 
maintained in small amounts, because of iron’s cytotoxicity (64). 
 
3.3.1 Regulation of cellular iron metabolism 
 
 Cellular iron homeostasis is regulated at the post-transcriptional level by the iron 
regulatory proteins 1 and 2 (IRP1 and IRP2). Target mRNAs that codify proteins involved 
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in iron regulation have iron responsive elements (IRE), which are cis-regulatory hairpin 
structures (63). Binding of IRP1 and IRP2 to the IREs is regulated by intracellular iron levels 
(65). 
  In iron-depleted cells, IRPs bind to the IREs present in the 5’-untranslated region 
(UTR) of the ferritin and ferroportin 1 genes, repressing their translation by preventing the 
binding of the small ribosomal subunit to the mRNA. Moreover, IRPs bind to the 5 IREs in 
the 3’-UTR of the TfR1 mRNA, leading to its stabilization and translation. This results in 
increased cellular iron uptake and decreased iron storage and export from the cells.  
 When cells are iron replete, IRP1 and IRP2 are inactivated, resulting in inhibition of 
TfR1 mRNA translation and translational de-repression of the ferritin and ferroportin 1 
genes. This leads to decreased iron absorption and increased iron storage and egress from 
the cells (66).  
 
3.4 Iron (de)regulation in neoplastic cells 
 
 In the past several years, the role of iron in neoplastic disease has been extensively 
studied (67). Results from several studies give evidence that cancer cells behave as “iron-
deficient” and are able to undermine the tightly physiological process of iron regulation in 
order to accumulate iron (67). Alterations in the expression of proteins related to iron 
metabolism, in neoplastic context, have been extensively reported and some are presented 
next. 
 
 One of the first findings that demonstrated the high requirements for iron was the 
upregulation of TfR1 in many tumors. This evidence of increased expression of TfR1, 
together with studies using anti-TfR1 monoclonal antibodies in different cells lines, suggest 
the fundamental role of iron in cancer cell proliferation (68-70).  
 
 Normal cells predominantly take up iron through binding of Tf to TfR1, which is then 
internalized via receptor-mediated endocytosis (71). A different mechanism of iron uptake 
has also been reported in cancer cells. In this process iron potentially enters the cells 
through a membrane-bound oxidoreductase, not involving the endocytosis of transferrin 
(65). This non-saturable, non-receptor-mediated process was first described in fetal rat 
hepatocytes by Trinder and colleagues (72). Subsequent studies demonstrated that this 
advantageous mechanism is also present in several cancer lines and after saturation of the 
TfR binding sites, there was still a marked increase in iron uptake (73-75).  
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 Serum ferritin is also increased in a number of neoplasias, such as liver cancer, 
neuroblastoma, colon cancer and breast cancer (76-79). Tumor cells typically have lower 
ferritin levels than cells from normal counterparts. Neoplastic cells from neuroblastomas are 
an exception, because they show higher intracellular ferritin content than normal cells (80). 
Ferritin, namely the heavy subunit (H-ferritin) sequesters excess iron, so its downregulation 
presumably increases iron accessibility (81). Furthermore, H-type ferritins may be involved 
in immunological antitumor responses, so its decrease potentially benefits cancer cell 
proliferation (82, 83). Additionally, genes associated with neoplastic transformation can also 
result in altered ferritin expression (84). Tsuji and colleagues have found that transfection 
with the adenovirus E1A repressed H-ferritin expression (85). The proto-oncogene c-myc 
seems to have the same effect of H-ferritin, besides increasing IRP2 expression (86). 
 
 Production of siderophore-like molecules by tumor cells has also been reported. 
Siderophores are organic molecules produced by microorganisms to acquire iron from the 
environment. When its acquisition is necessary, lipocalin 2, an innate immune protein, binds 
to sidephores to capture iron (87). Studies in breast cancer and leukemia cell lines report 
that lipocalin 2 is upregulated in these neoplasias, suggesting that cancer cells can pro-
actively increase cellular iron uptake by this mechanism (88, 89). 
 
 In a recent study, Torti’s group reported that prostate and breast cancer cells are 
capable of hepcidin production, leading to decreased ferroportin 1 expression and 
increased intracellular iron retention. The outcome was the promotion of cancer cell survival 
(90). 
  
3.5 Iron (de)regulation in breast cancer cells 
 
 Although studies are controversial, a large set of epidemiological, experimental and 
clinical evidences support the hypothesis that iron is strongly associated with breast cancer 
initiation and progression (91). This possibility is based primarily on the notion that cancer 
cells require iron for their nutrition and proliferation, and that iron may increase cancer risk 
through the formation of free radicals and production of oxidative damage (92).  
 
3.5.1 Epidemiological studies 
 
Epidemiologic studies regarding dietary iron intake have not shown consistent 
results. In a study by Stevens and colleagues, higher transferrin saturation and serum iron 
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were positively correlated with cancer risk, both in men and women (93). Mainous and 
colleagues reported that increased transferrin saturation was associated with increased 
cancer risk, but only when it was combined with high iron intake (94). 
Although several studies revealed positive correlations, a significant number of 
studies report inverse (95, 96) or null correlations (96). 
 
3.5.2 Genetic association studies 
 
 Another approach employed to study iron deregulation in breast cancer has been 
the study of its association with hereditary hemochromatosis (HH) major allelles (97). HH is 
an autosomal recessive disorder of iron metabolism, characterized by excessive dietary iron 
absorption and deposition in several tissues, resulting in cellular toxicity (98). Feder and 
colleagues identified a major-histocompatibility complex (MHC) class I-like molecule, 
designated as HFE, as being the candidate gene for HH (99).  
The majority of HH patients carry a missense mutation, which results in the substitution of 
a cysteine for a tyrosine at aminoacid 282, which is termed the C282Y mutation. A second 
mutation in the HFE gene results in the substitution of histidine for aspartate at amino acid 
63 and is termed the H63D mutation (100).  
 
 HFE has a role in iron regulation. Under normal condition, HFE forms a stable 
complex with TfR1, lowering its affinity to Tf (101). The C282Y mutation abolishes the ability 
of HFE to associate with β2-microglobulin (β2m) and prevents cell-surface expression, 
resulting in loss of function (102). H63D variants appear to form a salt bridge with a residue 
in the α2 loop of HFE that binds to TfR1, which possibly provides a molecular basis for its 
effect on iron homeostasis (98). 
 
 Both the C282Y and H63D HFE variants are highly prevalent in the general 
population and carriers of these polymorphisms frequently have higher transferrin saturation 
and ferritin levels than wild-type individuals (103). Given the fact that carriers are able to 
modulate body iron deposition, several studies were performed to analyze the relationship 
between HFE alleles and breast cancer.   
Kallianpur and co-workers reported a high prevalence of HFE C282Y alleles in women with 
breast cancer (104). In a large study performed by Osborne and colleagues, with 24469 
participants, C282Y homozygotes were at increased risk of developing breast cancer, but 
not C282Y/H63D heterozygotes (105). Moreover, Beckman reported that, in the context of 
multiple neoplasias, the interaction between the HFE and TfR alleles could be associated 
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with increased risk for cancer. Particularly, individuals with the HFE C282Y allele (homo- or 
heterozygotes), together with TfR Ser142/Ser142 genotype showed an increased 
frequency of breast cancer. This study found no association when each gene was analyzed 
in separate (106). 
An explanation for the lack of association between HFE major alleles and breast cancer in 
some studies can be found in a study performed by Hunt and colleagues, where they report 
that most C282Y heterozygotes do not absorb dietary iron more efficiently and do not 
present increased body iron stores (107). 
 
3.5.3 Animal Models 
 
Using the 7,12 dimethylbenz[a]anthracene (DMBA)-induced mammary cancer 
model in rats, Hrabinski and colleagues studied the influence of iron-replete or iron-deplete 
diets on tumor progression. The authors demonstrated that severe iron deficiency 
significantly lowers the incidence of mammary tumors in DMBA-treated rats and that this 
protective effect is diminished by supplying an iron rich diet to the rats during the promotion 
phase of tumorigenesis (108). 
 
3.5.4 Expression of iron-related proteins in cancer 
 
 Neoplastic cells have higher demands for iron, which is reflected in the gene 
expression profile manifested during tumor progression: through multiple pathways, breast 
cancer cells increase iron uptake and decrease iron efflux (97). These cells express higher 
levels of TfR1, compared to non-neoplastic breast tissue, which leads to increased iron 
intake, independently of intracellular iron levels (69). Studies in the MCF-7 mammary tumor 
cell line indicate that these cells produce Tf and TfR1, which confers selective advantage 
to these rapidly proliferating cells (109).  
 Serum ferritin expression levels were reported to be useful to stratify patients at 
higher risk of recurrence (110). Hypothesizing that the source of ferritin levels is the tumor 
mass and that this measure could reflect more directly the ferritin status of the tumor, Guner 
and associates studied tissue ferritin levels instead of serum levels. Besides reporting that 
there was no significant differences in the serum ferritin values between the cases of breast 
carcinoma and those with benign tumors, the authors showed higher tissue ferritin levels in 
breast cancer tissue, compared with benign or normal tissue (111). Studies by Rossielo 
revealed that ferritin staining was found mainly in the stroma and in macrophages 
surrounding neoplastic cells, which could explain contradictory results (112).  
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 Ferroportin 1 is downregulated in breast cancer cell lines and human breast tumors. 
This evidence, together with the upregulation of hepcidin, indicates that these cells acquire 
a “high intracellular iron” phenotype, which is associated with worse prognosis (113). In the 
same study, transfection of a mammary carcinoma cell line with an expression vector for 
ferroportin 1, resulted in decreased final tumor weight and rate of tumor growth in mice 
(113).  
Using a bioinformatics approach, the same group reported that the anti-export phenotype, 
characterized by low ferroportin 1 expression and high hepcidin expression, and pro-import 
phenotype, assigned to tumors showing high TfR1 expression and low HFE expression, 
were associated with increased metastasis rate in breast tumors (114).  
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4. TUMOR MICROENVIRONMENT 
4.1 Importance of the tumor microenvironment 
 
Current knowledge in breast cancer has been leading to a shift in perspective, 
providing a bigger body of evidence to support the idea that not only epithelial tumoral cells 
are relevant for tumor progression, but also their dynamic interactions with stromal cells 
(115-117).  
 Tumor microenvironment (TME) is the designation attributed to the set of cells, 
soluble factors, cytokines, extracellular matrix and cell-cell interactions that support 
neoplastic transformation, tumoral progression and invasion (118).  
As cells undergo neoplastic transformation, the expression of particular genes, 
which cannot be classified as oncogenes or tumor suppressor genes, changes and helps 
to promote high malignancy and metastasis (119). Ma and collaborators performed a 
microarray analysis of genes expressed during the transition from normal to ductal 
carcinoma in situ and from DCIS to invasive ductal carcinoma. Numerous genetic 
alterations were detected between these stages of tumor progression, in the epithelial and 
stromal compartments, which demonstrates that tumor-adjacent tissue co-evolves with 
epithelial cells (120). These data suggest that epithelial malignant cells require an 
appropriate support structure from the stromal cells to successfully acquire a full malignant 
potential (121). 
 The microenvironment of a breast carcinoma is occupied by a huge variety of 
resident cells, including adipocytes, fibroblasts, endothelial cells and newly formed blood 
vessels and migratory cells, such as leukocytes (122, 123). This stromal compartment plays 
an active role in tumorigenesis, through a wide range of pathways: immunosuppressing 
anti-tumoral responses, promoting resistance against therapy, stimulating angiogenesis 
through the release of pro-angiogenic factors, providing niches for metastatic cells or 
endorsing  neoplastic growth through the release of growth factors (118, 124). 
4.2 The role of macrophages  
 
One of the major components of the tumor milieu are the macrophages (125). These 
are tissue-resident innate immune effector cells, with important functions such as tissue 
homeostatic regulation and immunological clearance (126). Locally, these cells are 
responsible for the resolution of inflammation, clearance of apoptotic cells, production of 
cytokines and growth factors and antitumor immunity (127, 128). Van Furth in 1968 (129) 
proposed that the homeostasis of tissue-resident macrophages relies on the constant 
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recruitment of monocytes. Macrophage precursor’s monocytes circulate in the bloodstream, 
bone marrow and spleen and do not proliferate in a steady state. Inflammation, pathogen-
associated pattern recognition receptors or cytokines lead to the migration of monocytes to 
tissues and differentiation into inflammatory dendritic cells or macrophages (127). More 
recent evidences, however, contradict that concept and suggest that tissue macrophages 
do not derive from monocytes, but are derived from embryonic precursors that seed the 
tissues before birth and can maintain themselves in adulthood by self-renewal (128). 
Macrophages show a high level of plasticity, because they are able to assume 
diverse activation states depending on specific stimulation (130). The M1/M2 dicotomy is 
frequently used, in which macrophages are classified as M1, or classically activated, or M2, 
alternatively activated, depending on phenotypic characteristics, effector function, 
chemokine secretion and by the expression of specific receptors (131).  
 In response to “classic” stimulants, such as interferon-gamma (IFN-γ) or 
lipopolysaccharide (LPS) macrophages become “classically activated” and acquire a M1 
phenotype. These cells promote a Th1 response, killing of intracellular pathogens, efficient 
antigen presentation capacity and tumor destruction (132).  
Anti-inflammatory molecules, like glucocorticoid hormones, IL-4, IL-10 and IL-13 
induce an “alternatively activated” M2 phenotype. M2 macrophages show more a 
phagocytic activity, participate in Th2 responses, help with parasite clearance, attenuate 
inflammation, promote tumor progression and have immunoregulatory functions (132). 
Recalcati and colleagues investigated the differential expression of the genes 
involved in iron homeostasis and M1/M2 polarization. The authors reported that M1 
macrophages show a gene profile that favors iron sequestration, with ferroportin 1 
downregulation and ferritin upregulation (133). This strategy can be employed during 
infection and inflammation, in which pro-inflammatory macrophages sequester iron into 
ferritin to reduce iron availability to pathogens (134). On the other hand, M2 macrophages 
present enhanced iron release, because they upregulate ferroportin 1 expression and 
decrease ferritin induction (135).  
Macrophages can also be polarized into a “M2-like” phenotype. These cells share 
characteristic of both M1 and M2 sub-populations and have been named tumor-associated 
macrophages (TAM) (132).  
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4.3 The tumor-associated macrophages’ functions 
 
4.3.1 Tumor progression 
 
Tumor-associated macrophages abundantly populate solid tumor 
microenvironments and several studies have demonstrated that they are able to shift clinical 
outcomes (123).  
A large set of data supports the concept that macrophages help promoting tumor 
progression (121). Lin and colleagues reported that depletion of macrophages – through a 
homozygous null mutation of colony-stimulating factor 1 (CSF-1), which resulted in 
impairment of myeloid lineage development – decreased the recruitment of these immune 
cells, which was associated with delayed progression to malignancy and metastasis. 
Moreover, overexpression of CSF-1 accelerated tumor progression and metastatic seeding 
(136). Other studies reported that in macrophage-deficient mice, result of previous 
treatment with antisense oligonucleotides directed against Csf-1, there was a complete 
suppression of tumor growth (137). 
These data implicate a causal relationship between macrophage recruitment and 
worse outcome in neoplastic disease. In fact, increased TAM density correlates with 
advanced tumor progression and metastasis in over 80% of the clinical studies published 
on the subject (122), including human breast cancer (138). 
4.3.2 Tumor inflammation 
 
 The inflammatory process is responsible for leukocyte recruitment into the damaged 
tissue. In chronic inflammation, recruitment is persistent and these immune cells produce 
reactive oxygen and nitrogen species, which react with DNA, resulting in oxidative DNA 
damage and consequently, mutagenic events in epithelial cells (139). Furthermore, cells in 
the immunomicroenvironment produce growth factors and cytokines that can stimulate 
proliferation and survival of premalignant cells that suffered previous genetic alterations 
(121).  
4.3.3 Tumor cells invasion and extravasation 
 
 Macrophages are abundant in the invasive front of breast carcinoma and overlap 
with areas of basement-membrane breakdown and tumor cell egress (122). These cells 
produce metalloproteinases, especially MMP-7 and MMP-9 that have the ability to destroy 
the extracellular matrix (140). Moreover, tumor cells produce CSF-1, which promotes 
   - 21 - 
 
macrophage differentiation and survival (141). This cytokine induces macrophages to 
produce epidermal growth factor (EGF), which promotes the formation of elongated 
protrusions in carcinoma cells. CSF-1 released by tumor cells promote EGF expression by 
macrophages, which in turn promotes CSF-1 secretion by carcinoma cells, leading to a 
positive feedback in the paracrine loop, resulting in increased tumor cell invasion (142).  
4.3.4 Angiogenesis 
 Restrictions in nutrient bioavailability and oxygen, due to excessive proliferation, 
impair tumor growth beyond a certain size. Angiogenesis, which is the formation of new 
blood vessels, can lead to increased nutrient supply and also provides an essential exit path 
for potential metastasizing tumor cells into the bloodstream (143, 144). This process 
requires degradation of the extracellular matrix, proliferation and migration of capillary 
endothelial cells and their differentiation into functioning capillaries. Clinical evidence shows 
a correlation between local macrophage density and areas of intense angiogenesis, 
suggesting a role for immune cells in neovascularization (145). 
 The hypoxia inducible factor (HIF) is the major regulator of oxygen homeostasis. In 
oxygen-replete cells, HIF-1α is bound to the Von Hippel-Lindau protein (VHL), which causes 
HIF-1α to become ubiquitylated and targeted for proteasomal degradation. On the other 
hand, reduced oxygen availability results in HIF-1α accumulation, by inhibiting its ubiquitin-
proteasome degradation (146). HIF-1α is translocated into the nucleus and binds to the 
hypoxia-responsive elements (HREs), leading to the activation of hypoxia-response genes, 
such as the vascular endothelial growth factor (VEGF) and one of its receptors, VEGF-
receptor 1 (VEGFR1) (147). VEGF is the key mediator of angiogenesis (148) and exerts a 
chemotactic effect on TAMs (149). This cytokine is expressed by macrophages and tumor 
cells, in multiple types of human tumors (150). Circulating VEGF binds to VEGFR1 present 
of the surface of endothelial cells, inducing these cells to invade the underlying matrix and 
form new blood vessels (151).  
In summary, as extensively demonstrated by several authors, tumor growth and 
metastasis are influenced by the dynamic interplay between epithelial tumoral cells and 
cells from the tumor microenvironment (152). One prevailing vision is that tumoral cells 
secrete and release growth factors and cytokines that act like chemoattractrants and 
educative signals, which recruit certain cell types, leading to tumor progression. These 
stromal cells then produce growth factors and chemokines that support tumor cell nutrition, 
proliferation,  escape from immunosurveillance and extravasation into metastatic niches 
(120, 123).  
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5. CCL2 
   
 Chemokines are a group of small soluble proteins that mediate immune cell 
trafficking through the formation of concentration gradients (153). In their physiological 
context, chemokines are produced during an inflammatory process, resulting in the 
recruitment of leukocyte populations during a variety of processes, such as embryonic 
development, tissue injury, infection or tumor growth (154). 
 These chemotactic cytokines can be subdivided into 4 classes:  C–C, C–X–C, C and 
C–X3–C chemokines, depending on the location of the first two cysteines in their protein 
sequence (155). 
 Focusing on CC chemokines, these can be divided into various groups: allergenic, 
pro-inflammatory, haemofiltrate (HCC), developmental and homeostatic. Allergenic, pro-
inflammatory and HCC proteins are inducible chemokines, while those in the developmental 
and homeostasis subgroups are constitutively expressed (153). 
The role of chemokines in tumors has been extensively studied. Transcriptional profiling 
has shown that chemokines are not just leukocyte attractants, but they activate a restricted 
and distinct program in monocytes, including matrix metalloproteases and cytochrome 
CYP1B1, involved in carcinogenesis (131). 
 CCL2 (chemokine [(C-C motif)] ligand 2), also referred to as MCP-1 (monocyte 
chemoattractant protein-1), is an allergenic chemokine and one of the most studied in the 
context of tumor progression, especially in breast cancer (156).  
 
5.1 CCL2 secretion 
 
 CCL2 is produced by a variety of stromal cells, such as T lymphocytes (157), natural 
killer (NK) cells (158), fibroblasts (159) and monocytes (160). When properly stimulated, 
bone, epithelial, endothelial, adipose and muscular tissues are also accountable for its 
production (161). The effects of this chemokine are mediated through the CCL2-CCR2 axis. 
CCR2 (chemokine (C-C motif) receptor type 2) is mainly expressed in non-malignant 
epithelial cells, endothelial cells and macrophages (162).  
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5.2 CCL2 expression in breast cancer 
 
 Valkovic and co-workers studied the expression of CCL2 in breast invasive ductal 
carcinomas by immunostaining. Of the 27 samples, CCL2 immunoreactivity in epithelial 
cells was found in 15 samples (56%). This chemokine was also found expressed on tumor-
associated macrophages, in 23 of the 27 tumors (85%) (163). Latter studies by the same 
group reported that CCL2 expression was positively correlated with TAM infiltration, 
angiogenesis and poor survival (164). Another study by Fujimoto and colleagues revealed 
that CCL2 expression in the tumor stroma, but not in epithelial cells, was negatively 
associated with relapse-free survival (165). These data sustain the notion that CCL2 
supports tumor progression (166).  
 Expression of CCL2 has been associated with poor prognosis in a multitude of 
studies. In a study performed by Qian and colleagues, expression of CCL2 was associated 
with the increase of inflammatory monocytes in the pulmonary metastatic niche, facilitating 
extravasation of tumor cells (160). In another study performed by Li and co-workers, in a 
CCL2 knockout mouse model, a significant reduction of tumor burden, but a surprising 
increase in pulmonary metastasis, was reported (167).  
 Due to this relationship between CCL2 and cancer, it seemed reasonable to 
hypothesize that this chemokine could be a promising target for the development of novel 
anticancer therapeutics (168). 
 In the same study by Li and colleagues described above, they also investigated 
whether the administration of an anti-CCL2 monoclonal antibody to a murine model of 
breast cancer could influence tumor progression. They demonstrated a decrease in the 
number of spontaneous metastasis and reduction of established neoplastic lesions (167). 
Loberg and associates demonstrated that systemic administration of anti-CCL2 neutralizing 
antibodies significantly retarded tumor growth (169). Moreover, Fujimoto and colleagues 
reported that treating immunodeficient mice bearing human breast cancer cells with a 
neutralizing CCL2 antibody resulted in significant decrease in macrophage infiltration, 
angiogenic activity and tumor growth. This reduction was observed when the anti-CCL2 
antibody was administered in the setting of established lesions. Administration of the same 
antibody during tumor induction increased the frequency of neoplasms (165).  
Collectively, these data support the idea that CCL2 is required for the immunosurveillance 
of developing tumors, but may play a tumor-promoting function under certain conditions 
(167).  
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 On the contrary, cessation of the anti-CCL2 treatment resulted in an expected influx 
of monocytes into the metastatic site, enhancement of angiogenesis, metastatic disease 
and fatal outcome in a study performed by Bonapace and co-workers. The authors 
concluded that any tumor immunotherapy that only sequesters immune cells away from the 
tumor and does not reconfigure the surrounding cells or directly kill neoplastic cells, bear a 
risk of lethal rebound (170). 
 
5.3 CCL2 and iron  
 
In a recent study, published by Muckenthaler’s group, a panel of 62 genes was 
selected with the purpose of identifying novel modifiers of iron homeostasis. The results 
showed that depletion of CCL2 increased TfR1 protein expression, an important player in 
cellular iron acquisition. Furthermore, CCL2-deficient mice displayed massive iron overload 
in the spleen, mild iron overload in the liver and high expression of TfR1 mRNA and protein 
(171).  But the first study reporting an association between CCL2 expression and iron had 
been performed before by Lawless and colleagues. The aim of that study was to assess 
CCL2 serum levels in patients with HH and correlate the results with HFE genotypes and 
iron status. The authors reported that CCL2 serum levels were elevated in patients with the 
H63D variant but not in HH patients with the C282Y polymorphism (172).    
 Another evidence showing the relationship between CCL2 and iron is provided by 
Mitchell and colleagues who investigated the impact of HFE variants on CCL2 expression 
and iron accumulation in brain cells. They demonstrated that, regardless of cell type and 
HFE genotype, CCL2 secretion was increased by increasing intracellular iron levels and 
decreased by treatment with iron chelators, with the exception of cells carrying the C282Y 
variant (173). Thus, CCL2 seems to be influenced by cellular iron status, in the 
neuroinflammatory context.  
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AIMS 
 
 
 The principal aim of this work was to understand if the tumor iron status, in the breast 
cancer model, was related with the expression of CCL2.  
For that purpose, the specific aims were to: 
 Assess tissue iron deposition in normal tissue and DCIS and IDC lesions, in 
epithelial and stromal inflammatory cells; 
 
 Study CCL2 expression in epithelial cells and macrophages, in paraffin-embedded 
tissues of reduction mammoplasty samples, which account as controls, and 
neoplastic breast tissues (DCIS and IDC); 
 
 Assess the total number of macrophages (total macrophage infiltration) in all 
samples and the number of CCL2-positive macrophages in breast tissue; 
 
 Correlate CCL2 expression with established iron profiles in epithelial and stromal 
inflammatory cells, especially with proteins known to be deregulated during 
neoplastic progression; 
 
 Analyze if the HFE variants could modulate CCL2 expression in the breast cancer 
model; 
 
 Analyze if CCL2 expression could be correlated with clinical-pathological 
parameters of breast cancer behavior and prognosis.  
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MATERIALS AND METHODS 
1. Breast Cancer Tissue Samples 
 
A total of 54 invasive ductal carcinomas (IDC) and 34 ductal carcinomas in situ 
(DCIS), from formalin fixed, paraffin-embedded (FFPE) breast samples were used. These 
samples were previously collected from the archives of the Pathology Service, at Centro 
Hospitalar do Porto (Porto Hospital Centre, Porto, Portugal), for the PhD project in which 
this study is integrated and approved by the Ethics Committee. A total of 32 aesthetic 
reduction mammoplasty samples were also included, accounting as normal breast tissue.  
These samples are representative of primary breast tumors, collected from women 
that were diagnosed between 2004 and 2009, not subjected to any neoadjuvant treatment.  
 Haematoxylin-eosin slides correspondent to the 88 samples of primary tumors and 
32 reduction mammoplasty samples were also collected and analyzed by a pathologist, in 
order to select normal, in situ and invasive representative areas, whenever possible.  
 These FFPE blocks were used for all the techniques performed in these study: 
Tissue microarray (TMA) construction, Perls’ staining, immunohistochemistry, DNA 
extraction and PCR-RFLP. 
2. Tissue microarray construction 
 
 In 1998, Kononen and his colleagues developed the tissue microarray technology 
that enables researchers to sample up to 1000 tumors on one glass slide, which then can 
be analyzed by several histological and molecular procedures (174). This high-throughput 
technique facilitates the rapid analysis of hundreds of patient samples by a pathologist 
(175). 
  Staining of a few TMA sections in comparison to whole tissue sections offers a clear 
advantage with respect to the reduction of laboratory reagents, technician time and 
decrease of  technical variability during the staining and interpretative process (175). 
 The most frequent disapproval to TMA use is the small size of each tissue core – 
there is apprehension that due to tumor heterogeneity, biomarker scores obtained from 
small TMA cores will not accurately reflect scores obtained from whole sections. Moreover, 
there is a technical problem with tissue loss during sectioning, transfer and staining. The 
combination of sampling error during core extraction, core loss during slide preparation, and 
non-reactive cores leads to missing biomarker data and underestimation of the true 
incidence of a molecular marker. These problems can be minimized by the extraction of 
multiples cores per source blocks (174, 175). 
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The TMA builder used in this project is a metallic structure with 24 orifices, which allows 
the molding of a paraffin block, where the previously selected spots were inserted.  
Paraffin at 60ºC was poured into the TMA builder and a histology cassette was placed 
on top. Then it was left at -20ºC for the paraffin to solidify. Next, the paraffin block was 
carefully separated from the TMA builder, and an identification number was assigned to the 
block.  
 The next step was the inclusion of the areas of interest, previously selected by the 
pathologist, into the spots of the TMA block. This was performed using an extractor, which 
allows the selection of tissue areas with 2.0 mm. By applying force into the extractor, the 
area selected was removed from the donor block and then placed into the recipient block, 
following a previously designed map. More than 2 spots were obtained from the same block, 
in order to increase tissue representativity and TMA validation.  
TMA recipient blocks were then left at 60ºC for 10 minutes, to facilitate the adherence of 
the cores to the recipient paraffin’ walls. The final step was to place a heavy structure on 
top of the TMA block to facilitate the alignment of the spots.  
 Normal liver and lymph node tissue samples were also inserted, for correct slide 
orientation of cores and internal controls for stainings.  
TMA blocks were kept in room temperature until further techniques were performed.  
 
 
  
 
 
 
Figure 4: Representation of TMA construction.  (A) Cores previously selected in the 
corresponding slide stained with H&E can be extracted from the original paraffin block with the 
help of an extractor. (B) Extractor allows the selection of regions with 2.0 mm and placing in the 
recipient block. (C) Tissue sample is placed in the paraffin block built in the TMA builder, 
according to a designed map. Image adapted from (176). 
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 Apart from the controls, TMA blocks contained 452 spots from breast samples, of 
which 155 disappeared during alignment, sectioning or were lost during 
immunohistochemistry procedures.  
3. Heamatoxylin-eosin (H&E) staining 
 
TMA blocks were aligned, as previously described, and cut in a microtome in 2 μm 
sections. Slides were left for 5 minutes at 70ºC to increase tissue adherence to the glass 
surface and then placed at 37ºC until use. 
 After deparaffinization in 2 consecutive xylene baths, 5 minutes each, slides were 
rehydrated by immersion in absolute, 90% and 70% alcohol and then rinsed under running 
water. Slides were then submerged in Mayer’s hemalum solution (Merck Millipore, Billerica, 
MA, USA) 5 times, rinsed under running water for 10 minutes and subsequently submerged 
in eosin for 1 minute. After this, slides were rinsed under running water and sequentially 
dehydrated in 70%, 90% and absolute alcohol and 2 changes of xylene. Slides were 
mounted with Entellan (Merck Millipore, Billerica, MA, USA). 
H&E slides were evaluated under the light microscope by a pathologist in order to 
identify the type of lesion in each spot (normal, DCIS or IDC), blinded of diagnostic and 
clinical information regarding the original donor tissue.  
Lesions were further classified and coded as following, for statistical evaluation 
proceedings: 
 0 –Normal (from the reduction mammoplasty samples); 
 1 - Normal, from a sample diagnosed as DCIS; 
 2 – Normal, from a sample diagnosed as IDC; 
 3 – Pure DCIS (from a sample diagnosed as DCIS); 
 4 – DCIS, from a sample classified as in IDC; 
 5 – Pure IDC (from a sample diagnosed as IDC).  
 
4. Perls’ Prussian Blue staining 
 
Perls’s staining was performed to assess hemosiderin deposits in breast samples. 
Hemosiderin is a degradation product of ferritin, an iron storage complex (177) and this 
method provides a qualitative estimative, based on color intensity, of the amount of iron 
present in the tissue. 
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TMA blocks were cut in a microtome in 2 μm sections. Slides were left for 5 minutes 
at 70ºC to increase tissue adherence to the glass surface and then placed at 37ºC until the 
technique was performed. 
After deparaffinization and rehydration, as previously described, slides were stained 
with Butting solution (mixture of equal parts of chloridric acid 2% and potassium 
ferrocyanide 2% solutions), for 20 minutes at 60ºC and then rinsed in distilled water. 
Chloridric acid denatures the binding proteins of the hemosiderin molecule, leading to the 
release of ferric (3+) ions, which then bind to potassium ferrocyanide, resulting in the 
formation of the blue pigment, known as Prussian Blue.  
Tissues were counterstained with nuclear red for 4 minutes. Slides were then 
differentiated in absolute alcohol until a pink contrasting color was achieved. The slides with 
the stained samples were mounted with Entellan (Merck Millipore, Billerica, MA, USA).  
When performing Perls’ staining, a positive control tissue, such as an iron loaded 
liver tissue, was included in the experiment. Considering a situation of absence of 
hemosiderin deposits in the tissues, the positive control allows the researchers to 
understand if this absence is caused by lack of deposits or inaccuracy of the technique. 
 Slides with Perls’ staining were evaluated under the light microscope for detection 
of hemosiderin deposits, in the epithelial and stromal compartment separately. Each 
compartment was evaluated as 1, if at least one cell had hemosiderin deposits or 0, if no 
deposits were visualized.  
5. DAB-enhanced Perls’ technique 
 
 Considering that iron concentration in most tissues is low and the threshold of 
detection using the Perls’ method is hardly reached in epithelial cells (178), intensification 
with DAB can be performed to increase sensitivity, as described by Meguro (64). Samples 
were stained as described by this author, with an increase in incubation times of 25%, as 
described by Van Duijn and colleagues (179). 
TMA blocks were cut in a microtome in 4 μm sections and mounted in adhesive 
slides with 3-Aminopropyltriethoxysilane (APES). Slides were left for 5 minutes at 70ºC to 
increase tissue adherence to the glass surface and then placed at 37ºC until use. 
After deparaffinization in xylol and rehydration, as previously described, slides were stained 
with “freshly” prepared 1% potassium cyanide in distilled water (pH inferior to 5.5), for 40 
minutes. After this, slides were washed in distilled water. Samples were treated in methanol 
containing 0.01M NaN3 and 0.3% H2O2 for 75 minutes and then washed with 0.1M 
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phosphate buffer. For the intensification reaction, slides were incubated with a solution 
containing 0.025% 3.3'-diaminobenzidine (DAB) and 0.005% hydrogen peroxide (H2O2) in 
a 0.1M phosphate buffer, for 40 minutes. The reaction was stopped by rinsing in distilled 
water.  
Tissues were then counterstained with nuclear red for 4 minutes. Slides were 
differentiated in absolute alcohol until a pink contrasting color was achieved. The slides with 
the stained samples were mounted with Entellan (Merck Millipore, Billerica, MA, USA).  
 A negative control was used, as performed in Roschzttardz’s work (178), by omitting 
the incubation with potassium ferrocyanide. No staining was observed in the negative 
controls, showing that the staining was hemosiderin dependent and not due to peroxidase-
catalyzed degradation of H2O2, inducing the polymerization of DAB.   
As performed in routine Perls’ staining, a positive control tissue was also added to the 
experiment.  
 
6. Immunohistochemistry 
6.1 CCL2 immunohistochemistry 
 
 Immunostaining for detection of CCL2 expression was first performed using an 
antibody by R&D systems (MAB2791, R&D systems, Minneapolis). Datasheet suggested 
using lymph node as a positive control and a dilution of 8-25µg/µL. After studying the 
literature, and in order to optimize the protocol, dilution of 1:10, 1:40 and 1:100 were also 
tested. As the negative control, omission of primary antibody was used.  
 Immunohistochemistry was conducted according to manufacturer’s details using the 
Novocastra Novolink Detection System (Leica Biosystems). This detection system is 
systematically used in the Department and has been giving consistent results over a wide 
range of antibodies.  
 In the first tests performed in lymph node tissue, independently of the dilution used, 
non-previously described, strong unspecific staining in lymphocytes, background and a 
nuclear staining in leukocytes was visualized, as seen in Table 1.  
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Table 1: Representative images of CCL2 immunostaining performed on negative and positive 
controls for protocol optimization. Different dilutions were tested and antigen retrieval was 
performed using Dako Target Retrieval Solution. 
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 Considering that the lymph node is an immune-privileged site, overpopulated with 
immune cells, and CCL2 is a chemokine characterized by a mechanism of diffusion, this 
problem was disregarded and immunostaining using 1:60 and 1:100 dilutions was tested in 
breast tumor tissue.  
Table 2: Representative images of CCL2 immunohistochemistry performed on breast cancer 
tissue. Different dilutions were tested and antigen retrieval was performed using Dako Target 
Retrieval Solution. 
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 After visualization of slides, unspecific nuclear staining in epithelial cells was again 
detected (as seen in table 2). This staining was not previously reported in the literature 
analyzed. So, in order to solve this situation and optimize the immunohistochemistry 
protocol, different antigen retrieval methods were performed.  
 Immunohistochemistry, using lymph node tissue and a 1:100 dilution, was repeated, 
and the following antigen retrieval methods were performed:  
 Extran, in a microwave, for 15 minutes; 
 Pepsin (0.005%) based retrieval at 37ºC, in a heated chamber, for 45 minutes;  
 EDTA 1X in boiling water (100ºC), for 30 minutes; 
 Citraconic acid in boiling water (100ºC), for 45 minutes; 
 Tris-EDTA 1X in boiling water (100ºC), for 1 hour.   
 The same antigen retrieval methods were tested, in breast tumor tissue, using 1:60 
and 1:100 dilutions. 
 Despite the dilution or antigen retrieval method performed, predominant unspecific 
nuclear staining in lymphocytes (Table 3) and in epithelial cells (Table 4) was visualized. 
 
Table 3: Representative images of CCL2 immunohistochemistry performed on positive controls. 
Same dilution was tested (1:100), with different antigen retrieval methods. 
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Table 4: Representative images of CCL2 immunohistochemistry performed on breast cancer 
tissue. Same dilution was tested (1:100), with different antigen retrieval methods. 
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After these results, R&D systems was contacted, to provide technical support about 
the unspecific staining. The assistant suggest antibody revelation using the Avidin-Biotin 
Complex Method (ABC), instead of the Novocastra Novolink Detection System used 
previously. 
As demonstrated in table 5, the problems previously detected persisted and R&D 
Systems was again contacted. Tests performed by R&D Systems revealed that this 
antibody was detecting non-specific protein and so, the anti-CCL2 antibody by R&D 
systems was replaced by another antibody by Abcam. 
 
Table 5: Representative images of CCl2 immunohistochemistry performed on lymph node 
(positive control) and breast cancer tissue. Antigen retrieval with citrate buffer and revelation 
with the ABC method were performed. 
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 CCL2 immunohistochemistry protocol was optimized using the mouse anti-human 
monoclonal antibody CCL2, at a 1:25 dilution (ab9858, Abcam, Cambridge, United 
Kingdom) in TBS.BSA at 5%. 
 
6.2 CD68 immunohistochemistry 
 
 CD68 immunohistochemistry was performed with the mouse anti-human 
monoclonal antibody, at a 1:2000 dilution (clone KP-1, Cell Marque Corporation, California, 
USA) in TBS.BSA at 5%, using the Novolink detection system.  
6.3 Immunohistochemistry protocol 
 
 Immunostaining was performed using the same protocol for anti-CCL2 and anti-
CD68 antibodies.  
 For both stainings, lymph node tissue was used as the positive control (internal 
control in each TMA slide), as advised by the supplier, and omission of the antibody was 
used as the negative control. 
6.3.1 Sectioning 
 
TMA blocks previously constructed were cut in 2 μm sections and mounted in 
adhesive slides, in order to increase adhesion and prevent separation during technical 
procedures (180). Slides were left for 5 minutes at 70ºC to increase tissue adherence to the 
glass surface and then placed at 37ºC until use. 
6.3.2 Deparaffinization and hydration 
 
Slides were deparaffinized in 2 baths of xylene, 5 minutes each, and sequentially 
rehydrated in absolute alcohol, 90% and 70% and washed in water.  
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6.3.3 Antigen retrieval 
 
Antigen retrieval was then performed using Dako Target Retrieval Solution (Agilent 
Technologies, Denmark), at 10% in distilled water. Slides were placed in a staining jar, 
which was allocated in the water bath at approximately 100ºC, until retrieval solution turned 
blur (approximately 5 minutes) and 20 more minutes after that.  
 At the end of this time, the slides were taken out of the water bath and allowed to 
cool at room temperature.  
 During this time, the immunohistochemistry chamber was prepared. For this, 
absorbent paper was cut and placed in the bottom of the chamber and impregnated with 
TBS.  
6.3.4 Endogenous Peroxidase Block  
 
Slides were placed in the absorbent paper in order to eliminate the excess of antigen 
retrieval solution. Sections of interest in the slides were delineated with a hydrophobic pen 
(NovoPen, Novocastra, Leica Systems), which prevents waste of reagents by keeping 
liquids in tension. After this, slides were incubated with 3 drops of peroxidase block 
(Peroxidase Block, Novocastra Novolink Detection System, Leica Systems), in the 
immunohistochemistry chamber, for 5 minutes, at room temperature.  
 Slides were then rinsed twice in TBS, 5 minutes each.   
6.3.5 Protein Block 
 
Excess of TBS was eliminated from the slides by placing them in absorbent paper. 
Sections were again delineated with the hydrophobic pen and slides were incubated with 3 
drops of protein block (Protein Block, Novocastra Novolink Detection System), for 5 
minutes, at room temperature.  
6.3.6 Primary antibody 
 
The excess of protein block was drained from the slides and 150 μL of the primary 
antibody, at the correspondent dilutions, was poured in each glass slide. Slides were kept 
in the immunohistochemistry chamber, overnight, at 4ºC. 
6.3.7 Secondary antibody 
 
 The following day, slides were rinsed twice in TBS, 5 minutes each.  
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 Excess of TBS was eliminated from the slides by placing them in absorbent paper. 
Slides were then incubated with 3 drops of secondary antibody (Post-primary, Novocastra 
Novolink Detection System), for 30 minutes, in the immunohistochemistry chamber, at room 
temperature. Slides were then rinsed twice in TBS, 5 minutes each.   
6.3.8 Polymer 
 
 Slides were placed in the absorbent paper in order to eliminate the excess of the 
secondary antibody. Slides were incubated with 3 drops of the polymer (Polymer, 
Novocastra Novolink Detection System) for 30 minutes. Then, slides were rinsed twice in 
TBS, 5 minutes each. 
 Right before use, chromogen was prepared, using 50µL of DAB to every 1000 µL of 
substrate.  
6.3.9 Revelation  
 
 Revelation was performed with 3.3'-Diaminobenzidine (DAB). Slides were incubated 
with 150 μL of chromogen, until revelation occurred. Slides were then placed under running 
water for 10 minutes.  
6.3.10 Counterstaining and slide mounting 
 
Slides were immersed in Mayer’s hemalum solution for 5 to 6 times, and then placed 
under running water for 10 minutes. 
Slides were sequentially dehydrated in 70%, 90% and absolute alcohol and 2 
changes of xylene. At last, they were mounted with Entellan (Merck Millipore, Billerica, MA, 
USA). 
7. CCL2 scoring 
 
 TMA spots were then analyzed by a pathologist, in order to evaluate the area of 
expression and intensity of CCL2 staining. 
For the analysis of CCL2 epithelial stained area, a semi-quantitative approach was 
used and the following cut-off values were considered: 
- Score 0, which represents 0% of stained cells; 
- Score 1, 1 to 10% stained cells; 
- Score 2, 11 to 20% stained cells; 
- Score 3, 21 to 35% stained cells, 
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- Score 4, 36 to 50% stained cells; 
- Score 5, more than 50% cells presenting staining.  
For the analysis of CCL2 epithelial staining intensity, the following criteria were used: 
- Score 0: No staining; 
- Score 1: Weak staining; 
- Score 2: Moderate staining; 
- Score 3: Strong staining.  
 
 The final score was obtained by multiplying the area score and the intensity score. 
 
  Macrophages with CCL2 positive staining were counted in each spot. For this, 5 
HPFs (high power fields, 400X), per spot, were visualized under the light microscope and 
macrophages with CCL2 positive staining were counted. The values obtained from the 5 
HPFs were added in order to obtain the total spot count of CCL2 positive macrophages. 
 
8. Macrophage counting 
 
 CD68 staining was performed in TMA slides to help identify cells from the myeloid 
lineage and quantitatively evaluate its infiltration in the tumor nest and/or tumor stroma. 
 This antibody is a 110-kDa transmembrane glycoprotein highly expressed by 
monocytes and tissue macrophages (181).  
 Clone KP-1 was considered by Saito and colleagues to be an efficient antibody to 
identify tissue macrophages in a variety of tissues (182). CD68 recognized by this clone is 
resistant to conventional fixatives such as formalin, making it useful for diagnosis and 
routine analysis (183). 
On the other hand, CD68 is also expressed in fibroblasts, plasmacytoid T cells and 
neutrophils. This makes CD68 a pan-marker of cells of the myeloid lineage and not specific 
of macrophages (183). 
 To perform macrophage count in each spot, CD68 positive cells were counted in 5 
HFPs, taking into account CD68 immunoreactivity, cell and nuclear morphology, to 
distinguish between macrophages and other non-specifically stained cells. The values 
obtained from the 5 HPFs were added in order to obtain the total spot count of tissue 
macrophages.  
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9. DNA extraction 
9.1 Biologic samples 
 
 One paraffin block from each patient was selected, in order to perform DNA 
genotyping. FFPE blocks used for DNA extraction were the same as previously selected 
from Centro Hospitalar do Porto. 
In some cases extraction from FFPE blocks and PCR-RFLP was not possible to perform, 
due to extreme DNA degradation. In these cases, DNA extraction from peripheral blood 
was performed.  
 Peripheral blood was collected from women, diagnosed with Breast Cancer between 
2004 and 2009, which were followed by the Oncology Service, Centro Hospitalar do Porto. 
Blood was collected, by venipuncture into tubes already containing EDTA, an anticoagulant, 
as routinely performed in the Service.  
 
9.2 DNA extraction from FFPE blocks 
9.2.1 Deparafinization and hydration 
 
 Genomic DNA was extracted from FFPE breast sections using the Ultraprep Tissue 
DNA kit (AHN Biotechnologie, Nordhausen, Germany). FFPE blocks were trimmed in the 
microtome and first cuts were rejected, to avoid potentially more degraded DNA, due to air 
exposure, and contamination. Between blocks, the steel knife was cleaned with absolute 
ethanol. 
 Paraffin-blocks were cut in a microtome in 10 μm sections and 2 cuts from each 
block were used for DNA extraction. Slides were left for 5 minutes at 70ºC to increase tissue 
adherence to the glass surface and then placed at 37ºC until use. 
Glass slides were placed in supports and washed 3 times with Ottix (Diapath, 
Martinengo, Italy), 10 minutes each.  
Slides were next washed with absolute, 90% and 70% alcohol, 10 minutes each. 
After this, slides were washed with distilled water.  
Eppendorf tubes were previously prepared with the identification number of each 
FFPE block and 250 µL PB buffer and 20 µL proteinase K (Ultraprep Tissue DNA kit, AHN 
Biotechnologie, Nordhausen, Germany) were added to each tube. The samples were 
scraped from the glass slides with the help of a pipette tip and placed in the corresponding 
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eppendorf. These were incubated overnight in a thermomixer, at 55ºC, at 300 rpm, to 
facilitate tissue digestion.  
9.2.2 Extraction 
 
 The following day, 250 µL of AB buffer was added to each tube and these were 
vortexed for 30 seconds or until the pellet was resuspended.  
The solution in each tube was transferred into a new eppendorf with a spin column (±700 
µL) and samples were centrifuged for 1 minute and 40 seconds, at 14500 rpm. The flow-
through was then discarded and 400 µL of WB buffer was added to each tube, which was 
then centrifuged again for 1 minute and 40 seconds, at 14500 rpm.  
 Flow-through was discarded and spin columns were washed, twice, with 400 µL of 
70% alcohol. After the addition of 70% alcohol to the eppendorf tubes, these were 
centrifuged for 3 minutes and 30 seconds, at 14500 rpm.  
 At this point, flow-through was discarded and the columns were carefully transferred 
into 1.5 mL new eppendorf tubes, previously identified.  
Then, 40µL of EB buffer pre-heated at 70ºC was added to the center of each column and 
incubated at room temperature for 2 minutes. Finally, solutions were centrifuged for 1 
minute and 40 seconds, at 14500 rpm.  
Columns were discarded and eppendorf tubes carefully closed. 
9.2.3 DNA extraction from peripheral blood  
 
 Genomic DNA was isolated from peripheral blood leukocytes, using a modification 
from the original “salting out” method (184).  
 The first step consists of isolating mononuclear cells, through centrifugation of 
samples at 2000 rpm, for 20 minutes. This results in a cell distribution across the tube: on 
the bottom, a cellular phase, formed by erythrocytes and a buffy coat, composed of 
leukocytes; and on top a liquid phase, which contains the plasma. Plasma and the buffy 
coat were retrieved into a Falcon tube (50 mL), to which RCLB (Red Cell Lysis Buffer) was 
added until the final volume of 50 mL. Solution was homogenized by inversion and 
incubated for 10 minutes at room temperature. Next, centrifugation at 2000 rpm, for 10 
minutes at 4ºC, was performed. Supernatant was rejected and the pellet was washed 
repeatedly with RCLB and centrifuged until all erythrocytes were lysed and the pellet turned 
white. Next, 3.5 mL of TE-2 (Tris-EDTA) buffer was added to the pellet, plus 200 µL of SDS 
10% (Sodium Dodecyl Sulfate) and 10 µL of Proteinase K.  
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 After soft agitation, samples were incubated at 42ºC for 12 hours, allowing full cell 
digestion. Following this step, samples were transferred into a conical tube of 15 mL, to 
which 1 mL of NaCl 6M was added. This buffer leads to the precipitation of proteins and 
release of DNA. The solution was then vortexed and placed in a magnetic agitator for 10 
minutes. Next step was centrifugation at 3000 rpm, for 30 minutes, at 23ºC. This step 
allowed the separation of the protein component, which aggregates at the bottom of the 
eppendorf. Supernatant was transferred into a 15 mL Falcon and DNA precipitation was 
induced by adding 20 mL of absolute ethanol at -20ºC. Ethanol is responsible for the 
dehydration of the DNA molecule, and after repetitive inversions of the Falcon tube the DNA 
precipitate was visualized. This precipitate was washed twice with 5mL of 70% ethanol, at 
-20ºC, and resuspended in TE buffer in a 1.5 mL eppendorf. Finally, solution was left in an 
agitator for 12 hours and stored at -20ºC. 
9.2.4 DNA quantification 
 
 Genomic DNA in the samples, extracted from paraffin blocks or peripheral blood, 
was quantified using NanoDrop spectrophotometer. DNA concentration and the ratios of 
absorbance at 280nm and 260nm (A260/280) and 260nm and 230nm (A260/230) were analyzed. 
The A260/280 value gives information regarding DNA contamination of proteins and the A260/230 
values may indicate other contaminants, like phenols or salts.  
 The DNA was stored at -20ºC until PCR was performed.  
9.2.5 Polymerase Chain Reaction (PCR) 
 
 This technique, first introduced by Mullins in 1986 (185) allows the enzymatic de 
novo synthesis of a specific DNA sequence. Through repetitive cycles of denaturation, 
annealing of specific oligonucleotide primers and polymerase extension, the DNA sequence 
limited by the 2 primers is doubled in each cycle, mimicking the in vivo process of DNA 
replication (186).  
 PCR Reactions were performed using the Qiagen Multiplex PCR kit (Valencia, CA, 
USA) and the conditions for amplification are described below: 
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Table 6:  Description of the Multiplex PCR Components used for amplification of the C282Y 
and H63D variants of HFE. 
 
For the detection of the C282Y polymorphism the following primers were used: 5'-
CAA GTG CCT CCT TTG GTG AAG GTG ACA CAT-3' as the forward primer and 5’-CTC 
AGG CAC TCC TCT CAA CC-3’ as the reverse primer (primers from Metabion, 
Steinkirchen, Germany). These primers amplify a fragment with 343 bp.  
For the HFE H63D polymorphism, the following forward and reverse primers’ 
sequences were used:  5’-ACA TGG TTA AGG CCT GTT GC-3’ and 5’-GCC ACA TCT 
GGC TTA AAA TT-3’ (primers from Metabion, Steinkirchen, Germany). These primers 
amplify a fragment with 294 bp.  
Primers for detection of polymorphisms in the HFE gene were chosen according to Feder 
work (99). 
 Everytime PCR was performed, a negative control, consisting of mix without DNA 
template, was included.   
 The PCR program used for C282Y and H63D amplification was the following: an 
initial activation step at 95ºC, for 10 minutes, was performed to activate the HotStarTaq 
DNA polymerase; after this, 36 cycles, consisting of denaturation at 94ºC, for 30 seconds, 
annealing for 90s, at 58ºC, and extension for 90s, at 72ºC were performed. At last, reaction 
was extended at 72ºC, for 10 minutes. 
9.2.6 Electrophoresis 
 
 Electrophoresis is based on the principle that applying an electric field will force the 
negative molecules, such as DNA, to migrate into the positive pole, through an agarose or 
polyacrylamide matrix. This separates molecules by size, because smaller molecules move 
faster and migrate further through the gel (187).  
Component Volume/reaction Final concentration 
2× Multiplex PCR Mastermix 25 µL 1× 
Q-solution, 5× 5 µL 0.5× 
HFE C282Y/H63D Forward primer 100 µM 10 µM 
HFE C282Y/H63D Reverse primer 100 µM 10 µM 
Template DNA Variable ≤1 μg DNA 
Bi-distilled Water (Braun) Variable 
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 This technique was performed after PCR, in order to verify if amplification occurred.  
 First, agarose gel at 1.5% was prepared, mixing 4.5 g of agarose (GeneOn, 
Germany) with 300 mL of 1X TAE in an erlenmeyer flask. Then it was placed in a 
microwave, for 4 minutes, at full power. After this, 25µL of ethidium bromide (Invitrogen, 
Thermo Fisher Scientific, Massachusetts, USA) was added and the erlenmeyer flask was 
carefully stirred. When the agarose solution cooled down, it was poured slowly over a gel 
mold with the well combs in place. It was left at room temperature for 20-30 minutes, until 
completely solidified.  
. When the agarose gel was totally solidified it was placed in the electrophoresis unit, 
agarose gel was covered with 1X TAE and the combs were removed.  
 Then, 5 µL of the amplicon were added to 2 µL of loading buffer and the resulting 
solution was loaded to the wells of the gel. A 100 bp molecular weight ladder was placed in 
the first lane of the gel and the samples were loaded into the following wells. The gel was 
run for 1 hour, at 150 V.  
 The electrophoresis gel was visualized under ultraviolet light. Visualization of the 
fragments with the respective lengths, described above, indicates that amplification was 
successful and further techniques could be performed. 
9.2.7 PCR-RFLP 
 
 Restriction Fragment Length Polymorphism (RFLP) is one of the most used 
techniques to detect polymorphisms, especially those characterized by a single nucleotide 
variant. This technique consists of the amplification of a specific sequence containing the 
variant by PCR, followed by enzymatic restriction, which produces fragments with different 
lengths. Enzymes used are endonucleases that recognize and cut small specific DNA 
sequences (188). This technique takes advantage of the fact that single nucleotide 
polymorphisms (SNPs) are often responsible for the creation or abolishment of a restriction 
enzyme recognition site (189). The product of the enzymatic restriction is placed in an 
agarose or polyacrylamide gel and an electric field is applied. The fragments are separated 
by length, as described above.  
 To detect the presence or absence of the polymorphisms, PCR-RFLP technique 
was performed, using restriction enzymes and an agarose gel at 3%. The proceedings for 
the production of the agarose gel were the same as previously described, except that 9g of 
agarose was used, instead of 4,5g.  
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PCR tubes with the amplicons and the respective restriction mixes were placed at 37ºC in 
a heated chamber, overnight.   
9.2.7.1 C282Y polymorphism in the HFE gene 
 
 In order to analyze the presence of this variant in the HFE gene, 1µL of RsaI enzyme 
(10U/µL) was added to 1µL of enzyme buffer (both from Sigma-Aldrich, St. Louis, USA). 
 To identify the C282Y polymorphism, the type II endonuclease RsaI was used. This 
enzyme recognizes the restriction site GT’AC and the mutation creates a new restriction 
site, which is recognized by the enzyme (190). 
If the individual is homozygous dominant (CC), RsaI recognizes 1 restriction site and 2 
fragments are observed with 203 and 140 bp length. If the individual harbors the SNPs in 
the 2 alleles (YY), homozygous recessive, the endonuclease recognizes 2 restrictions sites, 
producing 3 fragments with 203, 111 and 29 bp.  If the individual is heterozygous (CY), the 
endonuclease produces the same fragments produced in homozygous dominant and 
recessive individuals: 203, 140, 111 and 29 bp.   
9.2.7.2 H63D polymorphism in the HFE gene 
 
 For the H63D polymorphism, 0.5µL of MboI enzyme (10U/µL) and 2µL of enzyme 
buffer was added to each sample (both from Metabion, Germany) 
 MboI, which is a type II restriction enzyme, identifies and -GATC sequence and 
cleaves the amplified region in 3 different sites.  
If the individual is homozygous dominant (HH), the enzyme localizes 2 cut sites in the 
sequence, producing 3 fragments with the following lengths: 138, 99 and 57 bp. In turn, if 
the individual is homozygous recessive (DD) one restriction site in abolished, producing 2 
different lengths fragments: 237 and 57 bp. In the presence of the variant in one allele, 
meaning that the individual is heterozygous for the H63D polymorphism (HD), 
endonuclease MboI produces the same fragments produced in homozygous dominant and 
recessive individuals: 237, 138, 99 and 57 bp.  
10. Statistical analysis 
 
 Data from breast samples were analyzed in 2 different manners: by lesion and by 
case.  
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10.1 Analysis by lesion 
 
 When performing this type of analysis, the diagnosis attributed to the TMA spot, 
regardless of the final diagnosis of the sample was considered. This means that from a case 
diagnosed as DCIS, normal and in situ regions were selected and evaluated separately; 
from a sample diagnosed as IDC, we selected normal, in situ and invasive regions. So, for 
each case, more than one different histological diagnosis was taken into account. Average 
values of each quantitative parameter, for different diagnosis, within the same case, were 
calculated. This allowed us to study different histological stages within the same case. 
10.2 Analysis by case 
 
 A different approach was the analysis considering the final diagnosis of each lesion, 
as classified by the pathologist. For this, we calculated the average value from each 
parameter, obtaining only one entry for each lesion.  
10.3 Statistical tests  
 
 Distribution and normality of data was first assessed by the Kolmogorov-Smirnov 
test, appropriate for analysis with more than 50 samples.  
Pearson’s Chi-Square was used to evaluate associations between categorical variables. To 
evaluate statistical differences between independent variables, in which one is categorical 
and the other is continuous, Mann-Whitney or Kruskal-Wallis tests were performed. The 
first one was used to determine statistical significance when 2 data sets were compared 
and Kruskal-Wallis test to compare between 3 set of data. The Dunn-Bonferroni post hoc 
method was performed following a significant Kruskal-Wallis test to determine the statistical 
significant between 2 specific groups. Spearman’s rank correlation test was applied to 
evaluate the relationships between continuous variables.  
Data was analyzed with IBM SPSS Statistics Versions 20.0 (SPSS Inc., IBM, 
Chicago, IL, USA) and statistical significance was accepted at p<0.05.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
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 1. DESCRIPTIVE STATISTICS 
 
 Apart from the normal liver and lymph node tissues inserted as controls, TMA blocks 
contained 452 spots from breast samples, of which 155 disappeared during alignment, 
sectioning or were lost during immunohistochemistry procedures.  
 For statistical purposes, the same lesions from the same case were grouped and 
the mean value of each parameter analyzed was taken into account. In total, 141 samples 
were obtained to analyze by lesion, as described in table 7.  
 Moreover, in the analysis by case, cores from the same donor tissue diagnosed with 
the same histological type were grouped and their mean score calculated. If the 
representative lesion was not extracted from the donor paraffin block or the representative 
core was lost during procedures previously described, the case was excluded from the 
analysis. Out of the 120 samples included in this study, 83 cases were considered, 
corresponding to 21 samples obtained from reduction mammoplasty, 27 of ductal 
carcinoma in situ and 35 of invasive ductal carcinomas (cf. Supplementary material, Table 
8).  
Table 7:  Tissue sample and core frequencies. 
Diagnosis 
Number of samples 
Tissue sample Lesion 
Normal sample (n=21) Normal 21 
DCIS (n=27) 
Normal in DCIS 17 
Pure DCIS 27 
IDC (n=35) 
Normal in IDC 28 
DCIS in IDC 13 
Pure IDC 35 
  
 Variables tested for the normality were iron deposition in epithelial and stromal 
inflammatory cells, epithelial CCL2 expression, expression of ferroportin 1 in lymphocytes 
and macrophages, total macrophage infiltration and infiltration of CCL2-positive 
macrophages.  
  The resulting p-value was inferior to 0.05 in all variables, so distribution was 
considered not normal and non-parametric tests were performed (cf. Supplementary 
material, Table 9).  
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2. DAB-ENHANCED PERLS’ STAINING 
  
 The presence of hemosiderin deposits was assessed in epithelial and stromal 
inflammatory cells by the DAB-enhanced Perls’ staining method. The degradation of H2O2 
by potassium ferrocyanide, together with the addition of DAB, results in the formation of a 
dark-brown coloration due to the polymerization of the chromogen. In epithelial and stromal 
cells, hemosiderin was found in the cytoplasm of these cells, as seen is figure 5.  
Figure 5: DAB-enhanced Perls’ staining of breast tumors, in epithelial (left) and stromal 
inflammatory cells (right). Original magnification of 400X (left) and 200X (right). 
 
 Iron deposition on epithelial and stromal inflammatory cells was assessed on 81 and 
70 samples, respectively.  
 In order to assess the percentage of cases presenting iron deposition in epithelial 
and stromal inflammatory cells, contingency tables were created in SPSS program and the 
values extracted from the corresponding tables. Graphs presented on figure 6 and 7 were 
designed from the values obtained.  
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Figure 6: Iron deposition in epithelial (blue) and in stromal inflammatory cells (green) in pure 
lesions. Chi-square test for iron deposition in stromal inflammatory cells: between normal and 
pure DCIS p=0.011; between normal and pure IDC p=0.001 (*p< 0.05, **p< 0.01, ***p< 0.001). 
Abbreviations: EC, epithelial cells; SIC, stromal inflammatory cells; DCIS, ductal carcinoma in 
situ; IDC, invasive ductal carcinoma. 
 
 The presence of hemosiderin deposits in epithelial and stromal inflammatory cells 
was more evident in carcinomas than in normal tissue, as illustrated in figure 6. 
 Taking only pure lesions into consideration, 3 out of 21 normal lesions presented 
hemosiderin deposits in epithelial cells (14.3%). There is an increase in iron deposition in 
carcinomas: 7 out of 25 in situ lesions (28.0%) and 12 out of 35 of invasive lesions (34.3%) 
had hemosiderin deposits in the cytoplasm of tumor cells (cf. Supplementary material, Table 
10).  
 Of the normal samples studied, 1 sample out of 13 (7.7%) presented hemosiderin 
deposits in stromal inflammatory cells. When looking at malignant lesions, 12 out of 24 pure 
DCIS lesions (50%) and 21 out of 33 pure IDC lesions (63.6%) presented iron deposition in 
macrophages and/or lymphocytes (cf. Supplementary material, Table 1w31). 
  
 Chi-square test was performed in order to assess differences between sub-groups 
of lesions. Statistically significant differences were found in iron deposition in stromal 
inflammatory cells, between sub-groups of lesions (p=0.003) (cf. Supplementary material, 
Tables 12 and 13). Chi-square test demonstrated that differences in the percentage of 
samples presenting iron deposition in stromal inflammatory cells are statistically significant 
when comparing normal tissue to pure DCIS lesions (p=0.011) (cf. Supplementary material, 
Table 14) and to pure IDC lesions (p=0.001) (cf. Supplementary material, Table 15 and 16).  
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 Remarkably, iron accumulation was already observed in the histologically “normal” 
tissue adjacent to carcinomas, as illustrated in Figure 7. 
 
 
 
 
 
 
 
 
 
 
Figure 7: Iron deposition in epithelial (blue) and in stromal inflammatory cells (green) in 
histologically “normal” adjacent tissue. Chi-square test for iron deposition in stromal 
inflammatory cells: p=0.037; between normal and normal adjacent to IDC lesions p=0.011 (*p< 
0.05, **p< 0.01, ***p< 0.001).  Abbreviations: EC, epithelial cells; SIC, stromal inflammatory 
cells; DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma. 
 
 Of the in situ cases, when the histologically “normal” tissue adjacent to the lesion 
was considered, 3 out of 15 samples analyzed presented hemosiderin deposits in epithelial 
cells (20%) and 6 out of 15 samples in stromal inflammatory cells (40%). When histologically 
“normal” regions from samples classified as IDC were studied, 10 out of 25 samples (40%) 
and 12 out of 24 samples (50%) presented iron deposition in epithelial and stromal 
inflammatory cells, respectively (cf. Supplementary material, Tables 17 and 18).  
 The presence of hemosiderin deposits in epithelial and in stromal inflammatory cells 
was more evident in histologically normal tissue adjacent to carcinomas than in control 
normal tissue, as illustrated in figure 7. 
 Chi-square test was performed. Statistically significant differences were found for 
iron deposition in stromal inflammatory cells, between sub-groups of lesions (p=0.037) (cf. 
Supplementary material, Tables 19 and 20). Differences in the percentage of samples 
presenting iron deposition in stromal inflammatory cells were statistically significant when 
comparing normal tissue to normal tissue adjacent to IDC lesions (p=0.011) (cf. 
Supplementary material, Tables 21, 22 and 23).  
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3. IMMUNOHISTOCHEMISTRY 
 
3.1 CCL2 expression  
 
 CCL2 immunostaining was detected on the cytoplasm of epithelial ductal cells and 
in some rare cases, in the nucleus. In the stromal compartment, monocytes, macrophages, 
neutrophils and fibroblasts also presented CCL2 expression in the cytoplasm. In figure 8, 
representative images of CCL2 staining in epithelial cells in normal, in situ and invasive 
lesions are presented.  
 
 
 
 
 
 
Figure 8: Representative images of epithelial CCL2 immunostaining in normal, DCIS (ductal 
carcinoma in situ) and IDC (invasive ductal carcinoma) cases. Original magnification 400X.  
 
3.1.1 CCL2 expression in epithelial cells 
  
  CCL2 staining in epithelial cells was assessed in 80 samples, out of the 83 
considered in this study. All normal samples were available for the evaluation of CCL2 
epithelial expression (n=21). Looking at carcinoma lesions, CCL2 expression was analyzed 
in 92.6% of in situ lesions (n=25) and 97.1% of invasive lesions (n=34). 
 Considering that the expression of CCL2 in epithelial cells does not follow a normal 
distribution, non-parametric tests were performed and the median value of expression and 
interquartile range, between brackets, were presented. Results are demonstrated in figure 
9, showing median values and error bars consisting of more or less 95% CI (confidence 
interval).  
Normal DCIS IDC 
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 In normal samples, median value of CCL2 staining was 4.00 (0.00-5.00). The 
median CCL2 expression in pure DCIS lesions was 4.80 (4.00-5.50) and 5.00 (4.00-7.50) 
in pure IDC lesions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Median CCL2 expression in normal, pure ductal carcinoma in situ (DCIS) and invasive 
ductal carcinoma (IDC) lesions. Dunn-Bonferroni test: between normal and pure IDC p=0.017 
(*p< 0.05, **p< 0.01, ***p< 0.001, versus precedent group). Error bars: 95% CI. Abbreviations: 
DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma. 
 
 
 Expression of CCL2 in epithelial cells was positively associated with malignancy 
(n=80; p=0.007; r= 0.299), as assessed by the Spearman’s rank correlation test (cf. 
Supplementary material, Table 24).   
 Kruskal-Wallis test was applied and revealed statistical differences between sub-
groups of lesions regarding epithelial CCL2 expression (p=0.022). Dunn-Bonferroni 
correction showed that statistical significance was only reached when comparing normal to 
pure IDC lesions (p=0.017) (cf. Supplementary material, Tables 25 and 26).  
 
 CCL2 expression in epithelial cells was also analyzed in the histologically “normal” 
tissue adjacent to carcinoma lesions and results are illustrated in figure 10. Increased 
expression of CCL2 was already evident in the histologically “normal” tissue. The median 
CCL2 expression in “normal” tissue adjacent to DCIS lesions (n=16) was 5.00 (4.25-5.00) 
and 5.00 (3.735-5.50) in normal tissue adjacent to IDC lesions (n=27).  
 
 
* 
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Figure 10: Median epithelial CCL2 expression in histologically normal tissue, adjacent to 
carcinoma lesions. Error bars: 95% CI. Abbreviations: DCIS, ductal carcinoma in situ; IDC, 
invasive ductal carcinoma. 
  
 Kruskal-Wallis test revealed no statistical differences in epithelial CCL2 expression 
between these sub-groups of lesions (p=0.067) (cf. Supplementary material, Table 27).  
 
3.1.2 CCL2 expression in macrophages 
 
 CCL2 expression was also studied in cells from the monocytic lineage and was 
assessed on 74 samples, consisting of 19 normal cases, 23 pure DCIS and 32 invasive 
ductal carcinomas. Expression of this chemokine was mainly observed on the cytoplasm of 
macrophages. Although other cells presented CCL2 expression, such as neutrophils and 
fibroblasts, only monocytic cells were considered. 
 In figure 11, images of immunohistochemistry for CD68 and CCL2, in the same 
tissue section, are presented. 
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Figure 11: Section of a DCIS (ductal carcinoma in situ) lesion, immunostained for CD68 (on the 
left) and CCL2 (on the right). A few examples of CCL2-positive macrophages are shown and 
marked with an *. Original magnification 400X. 
 
 The median count for CCL2-positive macrophages in normal spots was 3.00; in pure 
ductal in situ lesions the median value was of 16.00 (7.00-25.50) and 8.00 (2.50-36.50) in 
ductal invasive cases, as demonstrated in figure 12.  
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Infiltration of CCL2-positive macrophages in Pure Lesions. Dunn-Bonferroni test: 
between normal and pure DCIS p<0.001; between normal and pure IDC p=0.001 (*p< 0.05, **p< 
0.01, ***p< 0.001, versus precedent group). Error bars: 95% CI. Abbreviations: DCIS, ductal 
carcinoma in situ; IDC, invasive ductal carcinoma. 
   
 As assessed by the Spearman’s rank correlation coefficient, infiltration of CCL2-
positive macrophages was positively associated with malignancy (n=74; p=0.003; r = 0.335) 
(cf. Supplementary material, Table 28).  
* 
* 
* 
*** 
*** 
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 Kruskal-Wallis test was applied to compare differences between sub-groups of 
lesions, regarding the infiltration of macrophages expressing CCL2. The test revealed 
statistically significant differences (p<0.001). The Dunn-Bonferroni test revealed that 
differences were statistically significant when comparing normal samples to pure DCIS 
(p<0.001). The same occurs when comparing normal to pure IDC samples (p=0.001) (cf. 
Supplementary material, Tables 29 and 30). 
  
 Infiltration of CCL2-positive macrophages was also assessed in the histologically 
“normal” tissue adjacent to carcinoma lesions and results are present in figure 13. In 
“normal” tissue adjacent to DCIS lesions (n=12) the median count of CCL2-positive 
macrophages was 7.00 (3.00-14.00) and in the “normal” tissue adjacent to invasive lesions 
(n=24), the median value of the count of CCL2-positive macrophages was of 3.00 (1.50-
8.00).  
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Infiltration of CCL2-positive macrophages in normal adjacent tissue. Error bars: 95% 
CI. Abbreviations: DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma. 
 
 Kruskal-Wallis test revealed no statistical differences in the infiltration of CCL2-
positive macrophages between these sub-groups of lesions (p=0.069) (cf. Supplementary 
material, Table 31). 
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3.3 CD68 expression 
 
 CD68 immunohistochemistry was performed in order to facilitate macrophage 
counting and assess total macrophage infiltration. As explained previously, identification of 
macrophages was complemented by analysis of cell and nuclear morphology. 
 CD68 expression was detected mainly on the membrane of macrophages, but some 
diffusion into the cytoplasm was also observed.   
 In figure 14, representative images of CD68 staining in normal, in situ and invasive 
lesions are presented. 
 
 
 
 
 
 
Figure 14: Representative images of CD68 immunostaining in normal, DCIS (ductal carcinoma 
in situ) and IDC (invasive ductal carcinoma) cases. Original magnification 200X.  
 
 Infiltration of CD68-positive cells was assessed on 75 samples: 18 normal samples, 
23 in situ and 34 invasive cases. Macrophage infiltration was more evident in carcinoma 
than in normal mastectomy samples.  
 The median count of macrophages in normal tissues was 18.50 (10.00-47.00). In 
carcinoma lesions, the median value was of 74.00 (61.00-106.50) in in situ cases and of 
109.00 (91.00-189.00) in invasive lesions, as illustrated in figure 15.   
   
 
 
 
 
 
 
 
 
Normal DCIS IDC 
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Figure 15: Total macrophage infiltration in pure lesions. Dunn-Bonferroni test: between normal 
and pure DCIS p=0.003 and normal and pure IDC p<0.001 (*p< 0.05, **p< 0.01, ***p< 0.001, 
versus precedent group). Error bars: 95% CI. Abbreviations: DCIS, ductal carcinoma in situ; 
IDC, invasive ductal carcinoma.  
 
 According to the Spearman’s rank test, the number of macrophages in the tissues 
was positively associated with malignancy (n=75; p<0.001; r= 0.630) (cf. Supplementary 
material, Table 32).  
 Kruskal-Wallis test was performed and differences between sub-groups of pure 
lesions were statistically significant (p<0.001). Dunn-Bonferroni test revealed statistically 
significant differences when comparing normal to pure DCIS (p=0.003) and normal 
comparing to pure IDC (p<0.001) (cf. Supplementary material, Tables 33 and 34). 
  
 Total macrophage infiltration was also assessed in the “normal” tissue adjacent to 
neoplastic lesion. A total of 13 normal in DCIS and 26 normal in IDC samples were 
analyzed.  
 In the histologically “normal” tissue adjacent to DCIS lesions, the median count of 
macrophages was of 46.00 (33.00-49.00) and 36.00 (17.00-95.00) in “normal” tissue 
adjacent to invasive samples, as illustrated in figure 16. 
 
 
 
 
** 
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Figure 16: Total macrophage infiltration in normal tissue adjacent to carcinoma lesions. Error 
bars: 95% CI. Abbreviations: DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma. 
 
 
 Kruskal-Wallis test revealed no statistically significant differences in the total 
macrophage infiltration between these sub-groups of lesions (p=0.099) (cf. Supplementary 
material, Table 35). 
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3.4 Ferroportin 1 expression 
 
 Data regarding ferroportin 1 expression was obtained from the PhD thesis where 
this work is included (Marques et al., unpublished data). Our research group demonstrated 
previously that stromal inflammatory cells present alterations regarding ferroportin 1 
expression. (data not shown). In the context of this study, it was our goal to analyze if these 
alterations were due to the deposition of iron in the breast tissue.  
 In figure 17, a representative image of ferroportin 1 staining in an in situ sample is 
presented. Membrane and cytoplasmic staining in lymphocytes and macrophages was 
clearly evident in cases with this diagnosis.  
 
 
 
 
 
 
 
 
Figure 17: Section of a DCIS (ductal carcinoma in situ) lesion, immunostained for ferroportin 1. 
Stromal inflammatory cells present an evident immunostaining, particularly in the cytoplasm. 
Original magnification 400X. 
 
3.4.1 Ferroportin 1 expression in macrophages 
 
 Ferroportin 1 expression in macrophages was assessed on 54 samples: 3 normal 
samples, 21 pure DCIS and 30 pure IDC. 
 In normal samples the median expression of ferroportin 1 in macrophages was 1.00 
(1.50-1.00). In pure DCIS lesions the median expression was of 10.00 (8.00-10.00) and 
6.00 (4.00-8.00) in invasive lesions, as illustrated in figure 18.  
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Figure 18: Ferroportin 1 expression in macrophages, in pure lesions. Dunn-Bonferroni test: 
between normal and pure DCIS p=0.001; pure DCIS and pure IDC p<0.001 (*p< 0.05, **p< 0.01, 
***p< 0.001, versus precedent group). Error bars: 95% CI. Abbreviations: DCIS, ductal 
carcinoma in situ; IDC, invasive ductal carcinoma. 
 
 Kruskal-Wallis test was performed and statistically significant differences were found 
between sub-groups of pure lesions (p<0.001). According to the Dunn-Bonferroni 
correction, differences in ferroportin 1 expression in macrophages were statistically 
significant when comparing normal samples to pure DCIS (p=0.001) and pure DCIS to pure 
IDC (p<0.001). 
 
 Expression of ferroportin 1 in macrophages was also assessed in histologically 
“normal” tissue adjacent to carcinoma lesions. 
 Histologically “normal” tissue surrounding in situ lesions (n=4) presented a mean 
expression for ferroportin 1 of 12.50 (10.00-15.00) and 10.00 (6.00-10.00) in “normal” tissue 
next to invasive lesions (n=12), as demonstrated in figure 19.   
 
 
 
 
  
** 
*** 
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Figure 19: Ferroportin 1 expression in macrophages, in histologically “normal” tissue adjacent 
to carcinoma lesions. Dunn-Bonferroni test: between normal and “normal” tissue adjacent to 
DCIS lesions p=0.007 (*p< 0.05, **p< 0.01, ***p< 0.001, versus precedent group). Error bars: 
95% CI. Abbreviations: DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma. 
 
 Kruskal-Wallis test revealed statistically significant differences between sub-groups 
of lesions, regarding ferroportin 1 expression in macrophages (p=0.009). According to the 
Dunn-Bonferroni test, differences between sub-groups of lesions were only statistically 
significant when comparing normal tissue to “normal” tissue adjacent to DCIS lesions 
(p=0.007). 
 
3.4.2 Ferroportin 1 expression in lymphocytes 
 
 Ferroportin 1 expression in lymphocytes was assessed on 54 samples: 3 normal 
samples, 21 pure DCIS and 30 pure IDC. 
 In normal samples, the median expression of ferroportin 1 in lymphocytes was 1.50 
(1.00-3.50). In in situ lesions, median value obtained was 5.00 (3.00-7.33) and 5.50 (4.00-
10.00) in invasive lesions, as demonstrated in figure 20.   
  
** 
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Figure 20: Ferroportin 1 expression in lymphocytes, in pure lesions. Dunn-Bonferroni test: 
between normal pure IDC p=0.016 (*p< 0.05, **p< 0.01, ***p< 0.001, versus precedent group). 
Error bars: 95% CI. Abbreviations: DCIS, ductal carcinoma in situ; IDC, invasive ductal 
carcinoma. 
 
 Kruskal-Wallis test was applied and revealed statistically significant differences 
between sub-groups of lesions (p=0.011). Differences between normal samples and pure 
IDC were statistically significant (p=0.016). 
 
 Expression of ferroportin 1 in lymphocytes was also assessed in the histologically 
“normal” tissue adjacent to carcinoma lesions. Median expression of “normal” in DCIS 
samples was of 4.00 (4.00-9.50; n=3) and 7.00 (4.50-10.00; n=12) in “normal” tissue 
surrounding invasive lesions, as illustrated in figure 21.  
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Figure 21: Ferroportin 1 expression in lymphocytes, in histologically “normal” tissue adjacent to 
carcinoma lesions. Error bars: 95% CI. Abbreviations: DCIS, ductal carcinoma in situ; IDC, 
invasive ductal carcinoma. 
 
 Kruskal-Wallis test was performed and no statistically significant differences were 
found between sub-groups of lesions, regarding ferroportin 1 expression in lymphocytes 
(p=0.079). 
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4. STATISTICAL ANALYSIS 
 
4.1 CCL2 expression and macrophage infiltration 
 
 To analyze correlations between CCL2 staining in epithelial cells, total macrophage 
infiltration and infiltration of CCL2-positive macrophages, Spearman’s correlation tests were 
performed. All analysis were performed considering representative cases only (n=83).  
 Epithelial CCL2 expression was not associated with total macrophage infiltration 
(n=75; p=0.609) (cf. Supplementary material, Table 36), but was positively associated with 
infiltration of CCL2-positive macrophages (n=73; p=0.022; r=0.267) (cf. Supplementary 
material, Table 37). 
 Moreover, infiltration of CCL2-positive macrophages was positively correlated with 
total macrophage infiltration (n=73; p<0.001; r=0.488) (cf. Supplementary material, Table 
38). Linear correlation and respective r-squared values are presented in figure 22.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Correlation graph between infiltration of CCL2-positive macrophages and total 
macrophage infiltration. Linear r-squared value=0.253. 
 
4.2 Epithelial CCL2 expression and iron deposition 
 
 Next, possible correlations between expression of CCL2 in epithelial cells and iron 
deposition were assessed.  
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 Samples presenting iron deposits in epithelial cells show similar median CCL2 
immunostaining to samples without iron deposits, as illustrated in figure 23. Epithelial CCL2 
expression was not associated with iron deposition in epithelial cells (n=79; p=0.892) (cf. 
Supplementary material, Table 39). 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 23:  Median CCL2 expression in epithelial cells according to tissue iron deposition status 
in epithelial cells (p>0.05). Error bars: 95% CI.  
 
Epithelial CCL2 expression was, however, positively associated with iron deposition 
in stromal inflammatory cells (n=69; p=0.001) (cf. Supplementary material, Table 40). In the 
presence of hemosiderin deposits in lymphocytes and macrophages, median CCL2 
expression in epithelial cells was of 4.80 (3.00-5.00); in the absence of iron deposition in 
stromal inflammatory cells, epithelial CCL2 expression was of 5.00 (4.00-6.67), as 
illustrated in figure 24.  
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Figure 24:  Median CCL2 expression in epithelial cells according to tissue iron deposition status 
in stromal inflammatory cells. Error bars: 95% CI. 
 
4.3 Epithelial CCL2 expression and ferroportin 1 expression 
 
We assessed if ferroportin 1 expression in lymphocytes and macrophages was 
somehow correlated with epithelial CCL2 expression. Of note, FPN 1 expression in 
lymphocytes was not associated with iron deposition in either epithelial cells (n=56; 
p=0.302) (cf. Supplementary material, Table 41) or in stromal inflammatory cells (n=55; 
p=0.408) (cf. Supplementary material, Table 42) and FPN 1 expression in macrophages 
was also not associated with iron deposition in epithelial cells (n=56; p=0.645) (cf. 
Supplementary material, Table 43) or in stromal inflammatory cells (n=54; p=0.334) (cf. 
Supplementary material, Table 44).  
 As illustrated in figure 25, CCL2 expression in epithelial cells was positively 
associated with FPN 1 expression in lymphocytes (n=55; p=0.001; r= 0.428). It was not 
correlated with FPN 1 expression in macrophages (n=54; p=0.842).  
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Figure 25:  Correlation between CCL2 expression in epithelial cells and ferroportin 1 expression 
in lymphocytes (p=0.001). Linear r-squared value=0.200. 
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 5. HFE VARIANTS 
 
5.1 C282Y variant 
 
 From the 83 samples included in this study, 7 could not be amplified by PCR due to 
DNA degradation. PCR-RFLP technique was performed on 76 samples, consisting of 67 
samples classified as CC and 9 samples classified as CY. No homozygous recessive 
individuals were found in this study.  
 In order to assess the percentage of cases genotyped as CC or CY, contingency 
tables were created and the values extracted from the corresponding tables. Graph 
presented on figure 26 was designed from the values obtained. 
 
 
 
 
 
 
 
 
Figure 26: Percentage of samples genotyped as CC or CY by samples diagnosis. 
 Genotyping for the C282Y variant was possible in all normal samples (n=21) and all 
were classified as homozygous dominant. Of the DCIS samples, 3 out of 20 (15%) were 
classified as CY, heterozygous; of the IDC samples 17% were also heterozygous.  
 Chi-square test was performed in order to assess differences in the proportion of 
C282Y variants between sub-groups of lesions. No statistically significant differences were 
found between the presence of the C282Y variant and sample diagnosis (p=0.138) (cf. 
Supplementary material, Table 45). 
 The frequency of individuals with the C282Y variants was similar to the frequency 
found in the general population. However, considering its relative low frequency we did not 
performed further statistical tests with this variant. 
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5.2 H63D variant 
 
 From the 83 samples included in this study for the detection of the H63D variant, 18 
samples could not be amplified due to DNA degradation. A total of 36 cases were classified 
as homozygous dominant, 27 as heterozygous and 2 as homozygous recessive. 
 As performed for the C282Y variant, contingency tables were created and the values 
extracted from the corresponding tables. Graph presented on figure 27 was designed from 
the values obtained. 
 
 
 
 
 
 
 
 
Figure 27: Percentage of samples genotyped as HH, HD or DD by samples diagnosis. 
 Out of the 19 normal samples, 9 (47%) were classified as homozygous dominant 
and 10 (53%) as heterozygous. Considering in situ samples, 13 out of 19 (68%) were 
classified as homozygous dominant and 32% as heterozygous. From the invasive samples, 
52% (14 out of 27) were homozygous dominant, 41% (22 out of 27) were heterozygous and 
7% (2 out of 27) were homozygous recessive. 
 Chi-square test was performed in order to assess differences in the distribution of 
the variables analyzed. No statistically significant differences were found between the 
presence of the H63D variant and sample diagnosis (p=0.380). 
 Considering only this polymorphism, heterozygous and homozygous recessive 
individuals were grouped and Chi-square test was performed taken 2 sub-groups into 
account. No statistically significant association were found between the presence of the 
H63D variant and sample diagnosis (p=0.866) (cf. Supplementary material, Table 46).  
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5.2.1 H63D variant and tissue iron status 
 
 Given the role of HFE in regulating iron homeostasis (98), the influence of the H63D 
variant in tissue iron status was next evaluated.   
 Percentage of cases, from each genotype, presenting or not iron deposition in 
epithelial and stromal inflammatory cells, were extracted from contingency tables.   
 Chi-square test was performed to assess if differences in the distribution were 
statistically significant. No statistically significant differences were found in iron deposition 
in epithelial or stromal inflammatory cells, between H63D genotypes (p=0.288 and p=0.166, 
respectively) (cf. Supplementary material, Tables 47 and 48).   
 5.2.2 H63D variant and CCL2 expression 
 
 To detect differences in the median expression of CCL2 between genotypes, Mann-
Whitney’s test was performed, taking 2 sub-groups into consideration: homozygous 
dominant (HH) and another sub-group composed by heterozygous and homozygous 
recessive (HD+DD) individuals. This test was performed on 62 samples: 35 homozygous 
dominant (HH) and 27 heterozygous and homozygous recessive. As illustrated in figure 28, 
regarding CCL2 epithelial expression, no statistically differences were found between 
homozygous dominant and heterozygous or homozygous recessive individuals for the 
H63D allelles (p=0.545) (cf. Supplementary material, Table 49).  
 
 
 
 
 
 
 
 
 
 
 
Figure 28:  Median CCL2 expression in epithelial cells according to the genotype in epithelial 
cells. Mann Whitney’s U test: p-value>0.05. Error bars: 95% CI.   
- 79 - 
 
 6. CLINICO-PATHOLOGICAL ASSOCIATIONS 
 
6.1 Pathological and clinical parameters 
 
 Pathological and clinical features were obtained from interin pathological reports. 
The following parameters were considered for this study: 
 Tumor size; 
 Estrogen receptor (ER); 
 Progesterone receptor (PR); 
 Human epidermal growth factor 2 (HER-2); 
 Hormonal receptor status; 
 Molecular subtype, which is a system of breast cancer classification , based on gene 
expression profiles (191). Four molecular subtypes are typically considered: 
 Luminal A: characterized by positivity of the ER and/or the PR; HER-2 
negativity 
 Luminal B: characterized by positivity of the ER and/or the PR; HER-2 
positivity. 
 HER-2 amplification: characterized by ER and PR negativity; HER-2 
positivity; 
 Basal-like/Triple-negative: negativity of the ER, PR and HER-2.  
 Lymph Node involvement; 
 Leukocyte count, including total number of neutrophils, lymphocytes, monocytes, 
eosinophils and basophils per µL. 
 
6.2 Epithelial CCL2 expression 
 
 The only statistically significant clinical correlation of epithelial CCL2 expression was 
found with ER-negative status (n=25; p=0.021) (cf. Supplementary material, Table 50). A 
total of 25 DCIS samples were considered, 7 of which were ER-negative and 18 were ER-
positive. CCL2 expression was significantly higher in epithelial cells of ER-negative DCIS 
cases, as illustrated in figure 29.  
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Figure 29: Median CCL2 expression in epithelial cells in samples ER-negative and ER-positive. 
Mann-whitney’s U test: p=0.021. Error bars: 95% CI. Abbreviations: DCIS, Ductal carcinoma in 
situ; ER, estrogen receptor.  
 
 In invasive samples, CCL2 expression in epithelial cells was not associated with the 
estrogen receptor status (n=32; p=0.836) (cf. Supplementary material, Table 51).  
 Although borderline, epithelial CCL2 expression, was also positively associated with 
the total peripheral blood monocyte count at the time of diagnosis (n=55; p=0.050) (cf. 
Supplementary material, Table 52).  
 No significant associations were found between epithelial CCL2 expression and the 
other clinical features, namely: tumor size (n=57; p=0.332), progesterone receptor status 
(in 25 DCIS cases p=0.282 and in 32 IDC cases p=0.263), HER-2 status (n=55; p=0.575), 
molecular subtype (n=55; p=0.215) and lymph node involvement (n=33; p=0.817) (cf. 
Supplementary material, Table 53-56). 
6.3 Infiltration of CCL2-positive macrophages 
 
 There were no significant associations between the infiltration of CCL2-positive 
macrophages and any of the clinico-pathological features considered for this study.  
6.4 Total macrophage infiltration 
 
 There were no significant associations between total macrophage infiltration and 
any of clinico-pathological features considered for this study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
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 Efforts to understand the biology of breast cancer have generally focused on the 
study of alterations displayed by epithelial cells, but accumulating evidences suggest that 
cells in the tumor microenvironment also undergo alterations in response to stimuli sent by 
epithelial cells and consequently contribute to tumor progression (192). Moreover, data from 
different scientific fields of research suggest that in current cancer biology, it should be 
virtually impossible to address the importance of the tumor microenvironment without 
considering the role of iron (193). 
 The first goal of this thesis was to characterize normal control tissues, from aesthetic 
reduction mammoplasty samples and breast cancer samples, using the DAB-enhanced 
Perls’ staining technique. A higher percentage of breast cancer samples displayed 
hemosiderin deposits in epithelial tumor cells, comparing with normal samples. Remarkably, 
this pattern of iron deposition was evident not only in the established malignant lesions, but 
also in the hypothetically “normal” tissue adjacent to the representative breast lesion. 
 Neoplastic cells have high requirements for iron, due to their incessant proliferation. 
This results in iron deregulation favoring higher intracellular iron concentrations [9]. 
Alterations in the expression of iron-related proteins in the breast cancer context have been 
extensively studied. Increased expression of the transferrin receptor 1 (TfR1) in the surface 
of neoplastic cells is the most obvious argument for the importance of iron in tumor 
progression (194). As first demonstrated by Pinnix and colleagues, the deregulation of the 
ferroportin/hepcidin axis may be central in breast tumor progression (113). Moreover, Chen 
and colleagues, validating a previous work by Zhang and co-workers (195), recently 
reported that the ferroportin 1 reduction in epithelial cells was associated with increased 
concentration of ferritin, the central iron storage protein. Increased intracellular iron levels 
observed, reflected by the concentration of the ferritin light chain, suggest that actively 
proliferating neoplastic cells have a constant supply of iron, necessary for metabolic 
reactions (196).  
In the study here presented, established lesions (pure DCIS and pure IDC) display 
iron deposition in the epithelial compartment, characteristic of actively proliferating tumor 
cells. Moreover, histologically “normal” tissue adjacent to these lesions also present 
hemosiderin deposits. These results led us to hypothesize that the histologically “normal” 
tissue adjacent to carcinomas already presents alterations that predispose the 
microenvironment to acquire more iron for metabolic processes. So iron deregulation may 
be previous to the establishment of the pure lesions and is already present in non-malignant 
lesions, such as hyperplasias, facilitating epithelial cell proliferation, dysplasia and the 
potential accumulation of mutations (27).   
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 Iron deposition was not limited to epithelial cells. Increased iron deposition was also 
observed in lymphocytes and/or macrophages, especially in carcinoma samples.  
 Macrophages are known to be specialized cells in handling iron at the systemic level 
(197) and erythrophagocytosis is a representative example. This process is performed by 
splenic and hepatic macrophages, which engulf senescent and damaged erythrocytes, in 
order to recycle iron for the production of hemoglobin in new red blood cells (197). In 
response to heme released from erythrophagocytosis of senescent red blood cells, 
ferroportin 1 expression in macrophages is upregulated (198). In situations of local increase 
of blood flow, such as angiogenesis, macrophages mimic this process by delivering iron to 
facilitate tumor growth (193). Lymphocytes are also capable of uptaking non-transferrin-
bound iron, as demonstrated by a recent study by Pinto and colleagues (199), where they 
provided evidence supporting the hypothesis that circulating immune cells may have a 
surveillance role in controlling potential iron toxicity (193).  
 Phenotypic characterization of macrophages, focusing on the expression of iron-
associated proteins, has become a point of interest. This is because iron may shape 
macrophage polarization, but the polarization of macrophages can also have important 
effects on iron metabolism (133). Inflammatory or M1 macrophages are characterized by 
iron retention, due to increased induction of ferritin secretion and downregulation of 
ferroportin 1 expression. On the other hand, M2 macrophages act as iron-deficient and 
present lower intracellular iron levels than M1 macrophages. In Corna’s work, these 
macrophages were characterized by higher TfR1 and FPN 1 expression and suppression 
of ferritin (200).  
 Description of the populations of macrophages present in the tumor 
microenvironment is beyond the scope of this work, but it was reported that these cells 
mainly have a M2-like phenotype (131). Unpublished work performed by our group reported 
that, although the tumor microenvironment consists of cells with both activation phenotypes, 
M2-like macrophages are predominant. Recalcati and colleagues reported that M2 
macrophages are capable of exporting iron in vitro. In the same study, in which a tumor cell 
line was grown in the conditioned media of M2 macrophages, the authors concluded that 
tumor-associated macrophages may also exacerbate the neoplastic disease by supplying 
iron to actively proliferating tumor cells (133). As also reported in the work here presented, 
increased ferroportin 1 expression in lymphocytes and macrophages, particularly in the 
transition to the in situ state may reinforce the iron exporting phenotype suggested for 
stromal inflammatory cells.  
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 Results from our study suggest that circulating macrophages and lymphocytes, 
loaded with iron, migrate into the tumor site. Locally, due to an increase in ferroportin 1 
expression, these stromal inflammatory cells release iron, important for the proliferation of 
neoplastic cells. As in epithelial cells, iron deposition in stromal inflammatory cells is already 
visible in the histologically “normal” tissue adjacent to carcinomas. 
 
  Chemokines are best known for their ability to induce the migration of cells and 
significantly contribute to cancer progression and metastasis (201). Taken this into 
consideration, expression of CCL2 in epithelial and stromal inflammatory cells was analyzed 
by immunohistochemistry. CCL2 has been described an as important chemokine in breast 
cancer context (156). Results from several authors demonstrate that CCL2 has little or no 
effect on carcinoma cell proliferation or survival (170, 202), but promotes angiogenesis and 
the release of a wide array of proangiogenic factors and enzymes, such as 
metalloproteinases (203, 204). 
 In this study, an increased expression of CCL2 in epithelial and stromal inflammatory 
cells was observed with increased malignancy. This correlation was detected not only in 
established breast cancer lesions, but also in the hypothetically “normal” tissue adjacent to 
these lesions.   
 Mantovani was the first to report that tumor-derived chemokines could be 
responsible for the attraction of monocytes to the tumor nest, where they could enhance 
tumor progression, by supplying growth and angiogenic factors (125). In our study, although 
there was no significant association between tumor CCL2 expression and total macrophage 
infiltration, there was a significant association with the infiltration of CCL2-positive 
macrophages.  
 The evidence of a significant association between epithelial CCL2 expression and 
the infiltration of CCL2-positive macrophages consolidates the idea of a paracrine signaling 
pathway. Several authors demonstrated the existence of this pathway, in which tumor cells 
produce CCL2, responsible for the egress of CCR2-positive monocytes from the bone 
marrow into the tumor area (205). Moreover, tissue macrophages also secrete CCL2, 
recruiting more macrophages, as demonstrated by Fujimoto and colleagues (165), forming 
a paracrine signaling pathway. Furthermore, the infiltration of CCL2-positive macrophages 
was positively associated with the total macrophage infiltration. These results suggest that, 
as proposed by Fujimoto and colleagues, CCL2 produced by macrophages, attracted by 
CCL2 produced by tumor cells, is accountable for the attraction of macrophages from the 
bone marrow into the breast tumor milieu (165).  
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 Epithelial CCL2 expression was already evident in the histologically “normal” tissue 
adjacent to carcinomas. One can hypothesize that histologically “normal” tissue already 
presents deregulation, which may be responsible for the secretion of this chemokine. 
Through the paracrine signaling pathway previously suggested, epithelial expression of 
CCL2 may result in infiltration of CCL2-positive macrophages, which are also increased in 
pre-malignant tissue, facilitating malignant progression. 
 In this study, a gradual increase in the amount of infiltrating macrophages, CD68-
positive cells, from normal breast to ductal carcinoma in situ and invasive ductal carcinoma 
was evident. This increase in total macrophage infiltration was already visible in the 
hypothetically “normal” tissue adjacent to carcinoma lesions. As reported by several 
authors, there is a positive correlation between the number of tumor-associated 
macrophages and malignancy (138), and monocytes are often already increased at a very 
early stage of tumor development (206), as observed in the work here reported. This 
observation may be explained by the paracrine signaling pathway and by the fact that in the 
histologically “normal” tissue adjacent to carcinomas there is already an increase in the 
infiltration of CCL2-positive macrophages.  
 
  
 Influence of iron status in CCL2 expression was already demonstrated by Mitchell 
and colleagues (173). In other studies, not related to neoplastic disease, alterations in iron 
levels, by supplementation or administration of iron chelators, also influenced CCL2 protein 
levels (207-210). Considering all the studies and the role of macrophages in iron 
homeostasis and that these cells are attracted into the tumor microenvironment by CCL2, 
we hypothesized if CCL2 could, in part, be associated with iron deregulation, in breast 
cancer context. 
 Herein, the presence of hemosiderin deposits in stromal inflammatory cells was 
positively associated with increased CCL2 expression in epithelial cells. This significant 
association may suggest iron as a putative driving force to enhance CCL2 expression in the 
breast tumor environment, as previously described by Mitchell and colleagues in the 
neuroinflammatory context (173). The evident increase in iron deposition in the 
histologically “normal” tissue adjacent to carcinomas could explain the visible increase in 
CCL2 expression in these same stages. Alternatively, CCL2 expression could be the driving 
force to increase iron deposition. Our results suggest that iron loaded leukocytes may be 
attracted to pre-malignant sites by CCL2. At the tumor site, macrophages and lymphocytes 
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release iron, by upregulating the expression of ferroportin 1, which results in increased 
CCL2 expression and infiltration of more CCL2-positive macrophages.   
 Lawless and colleagues performed a study in which the presence of the HFE H63D 
variant was associated with the increase in CCL2 serum levels (172). In a study performed 
by Mitchell and co-workers, using a neuroblastoma cell line, the presence of the H63D 
variant was also associated with increased CCL2 expression (173). These studies led us to 
analyze if the HFE variants could influence CCL2 expression in breast cancer context. In 
our study no statistically significant association with HFE variant alleles was found. The lack 
of association between any of the HFE variants and CCL2 expression can be explained by 
the small number of heterozygous and homozygous recessive individuals in this study. Also, 
we cannot ignore different methodologies used in these studies: in the study by Mitchell in 
vitro experiments were performed, and Lawless used peripheral blood samples. One can 
hypothesize that locally, HFE variants do not play an important role in regulating CCL2 
expression.  
 Delaby and colleagues demonstrated that ferroportin 1 expression in macrophages 
and lymphocytes was mainly regulated by iron levels, putatively by the IRP-IRE system 
(198). In our study the expression of ferroportin 1 in lymphocytes and macrophages was 
not significantly associated with iron deposition, suggesting the existence of another 
possible player involved in the setting of an iron exporting phenotype in stromal 
inflammatory cells.  
Considering these results, we hypothesized that CCL2 could be associated with 
ferroportin 1 expression. We found that the expression of this iron exporter in lymphocytes, 
but not in macrophages, was significantly correlated with CCL2 expression in epithelial 
cells. This result suggests a novel putative role for this chemokine as a modulator of the 
iron export phenotype in stromal cells.  
 When circulating leukocytes arrive at the tumor site, the expression of CCL2 by 
epithelial cells may be a key factor in upregulating the expression of ferroportin 1 in 
lymphocytes. Although no correlation was found with the expression of this exporter in 
macrophages, reports have demonstrated that M2 macrophages, the most frequent in the 
tumor microenvironment, have an iron-exporting phenotype (133). Also, other players may 
attract macrophages into the tumor site and promote the “iron-export phenotype”. Induction 
of HO-1 expression in M2-macrophages seems to play a role in the iron release-prone 
phenotype of these cells. Heme in the new vessels can be a cause for the upregulation of 
HO-1 and the establishment of the iron-exporting phenotype (133).   
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 In this study, CCL2 expression was associated with ER-negative status, one of the 
classical biomarkers of breast cancer negative prognosis. As reported by Chavey and 
colleagues (211), CCL2 expression was increased in ER-negative tumors. Opposite to 
reported by Svensson and colleagues (212), we observed that estrogen-receptor negative 
samples showed higher levels of CCL2 expression. Different methodologies performed may 
explained opposite results. In our study, tumor CCL2 expression was analyzed, whereas in 
Svensson’s work extracellular CCL2 levels were considered. Moreover, for our study pre- 
and postmenopausal women were selected, while in the study previously reported only 
post-menopausal women were studied. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
CONCLUSIONS 
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 This study provides new data regarding the role of iron in breast cancer. Moreover, 
this deregulation is not limited to epithelial cells, because stromal inflammatory cells also 
show increased hemosiderin deposition, associated with increased malignancy. Striking 
increase in ferroportin 1 (FPN 1) expression in these cells, especially in the transition to the 
pre-invasive stage (DCIS), suggests that macrophages and lymphocytes may contribute to 
breast tumor progression, by supplying iron for actively proliferating breast tumor cells. 
 Herein, new considerations regarding the role of CCL2 in breast tumor promotion 
are described. Associations between epithelial CCL2 expression and infiltration of CCL2-
positive macrophages, together with the association between infiltration of CCL2-positive 
macrophages and total macrophage infiltration suggest a putative paracrine signaling 
pathway. Considering the role of macrophages in breast tumor, we hypothesize that CCL2 
and this paracrine signaling pathway plays a detrimental part in breast tumor progression, 
by facilitating extravasation and metastasis. 
 Analyzing the results obtained in this work, we propose the following mechanism, 
illustrated in figure 30: circulating macrophages and lymphocytes, described as actively iron 
storing cells, are attracted into the tumor site by CCL2 produced by neoplastic cells. When 
macrophages and lymphocytes arrive at the tumor milieu, FPN 1 expression is upregulated, 
at least partially by the expression of CCL2, and iron is supplied for non-malignant cells. 
Iron is then responsible for the proliferation of transformed malignant cells and the increase 
in epithelial CCL2 expression, which may trigger the paracrine signaling pathway. CCL2 
secreted by epithelial cells is responsible for the attraction of more CCR2-positive 
macrophages, which secrete CCL2 and consequently attract circulating monocytes, 
through a stromal cell amplifying system. This results in increased macrophage infiltration 
and increased supply of iron for actively proliferating neoplastic cells. 
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Figure 30: Proposed mechanism for the CCL2-induced pathway: CCL2 (green circles), 
produced by breast tumor cells, attract circulating CCR2-positive cells, such as macrophages 
and lymphocytes, which are iron-loaded. When these stromal inflammatory cells arrive to the 
tumor microenvironment, FPN 1 expression is upregulated, partially by the expression of CCL2, 
and iron (Fe) is supplied for proliferating epithelial cells. Iron supplied by macrophages and 
lymphocytes leads to increased proliferation and CCL2 secretion by tumor cells, triggering the 
paracrine signalling pathway, between tumor and immune cells. Macrophages are also 
accountable for the production of CCL2, resulting in increased leukocyte infiltration and 
increased iron supply for proliferating neoplastic cells.  
 
   
 In conclusion, this work reports that stromal inflammatory cells, as demonstrated by 
increased FPN 1 expression and hemosiderin deposition, play a role in supplying iron to 
actively proliferating tumor cells. Moreover CCL2, whose expression may be putatively 
enhanced by increased iron deposition in stromal inflammatory cells, contributes not only 
to increase macrophage infiltration into the tumor microenvironment, but also may play a 
role in regulating tumor iron nutrition and progression.
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 1. DESCRIPTIVE STATISTICS 
 
1.1 Tissue sample and core frequencies 
 
Table 8: Frequencies and percentages of lesions considered in this study. 
 
 
 
 
 
 
 
 
 
 
 
Table 9: Table demonstrating the p-value obtained from the Kolmogorov-Smirnov test, 
performed in order to assess the distribution and normality of data. 
Tests of Normality 
 Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
CCL2 expression in 
epithelial cells 
,296 59 ,000 ,866 59 ,000 
Iron deposition in epithelial 
cells 
,414 59 ,000 ,606 59 ,000 
Iron deposition in stromal 
inflammatory cells 
,379 59 ,000 ,628 59 ,000 
Ferroportin 1 expression in 
lymphocytes 
,149 59 ,002 ,932 59 ,003 
Ferroportin 1 expression in 
macrophages 
,151 59 ,002 ,955 59 ,029 
Total macrophage 
infiltration 
,163 59 ,000 ,835 59 ,000 
Infiltration of CCL2-positive 
macrophages 
,241 59 ,000 ,641 59 ,000 
a. Lilliefors Significance Correction 
Lesion Diagnosis 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
Normal 21 14,9 14,9 14,9 
Normal in DCIS 17 12,1 12,1 27,0 
Normal in IDC 28 19,9 19,9 46,8 
Pure DCIS 27 19,1 19,1 66,0 
DCIS in IDC 13 9,2 9,2 75,2 
Pure IDC 35 24,8 24,8 100,0 
Total 141 100,0 100,0  
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 2. DAB-ENHANCED PERLS’ STAINING 
 
2.1 Iron deposition in pure lesions 
 
Table 10: Contingency table demonstrating the frequencies and percentages of normal, 
pure DCIS and pure IDC samples presenting iron deposition in epithelial cells. 
Crosstab 
 Iron deposition in epithelial cells Total 
Absence Presence 
Diagnosis 
Normal 
Count 18 3 21 
% within Diagnosis 85,7% 14,3% 100,0% 
% within Iron deposition in 
epithelial cells 
30,5% 13,6% 25,9% 
% of Total 22,2% 3,7% 25,9% 
Pure DCIS 
Count 18 7 25 
% within Diagnosis 72,0% 28,0% 100,0% 
% within Iron deposition in 
epithelial cells 
30,5% 31,8% 30,9% 
% of Total 22,2% 8,6% 30,9% 
Pure IDC 
Count 23 12 35 
% within Diagnosis 65,7% 34,3% 100,0% 
% within Iron deposition in 
epithelial cells 
39,0% 54,5% 43,2% 
% of Total 28,4% 14,8% 43,2% 
Total 
Count 59 22 81 
% within Diagnosis 72,8% 27,2% 100,0% 
% within Iron deposition in 
epithelial cells 
100,0% 100,0% 100,0% 
% of Total 72,8% 27,2% 100,0% 
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Table 11: Contingency table demonstrating the frequency and percentage of normal, pure 
DCIS and pure IDC samples with iron deposition in stromal inflammatory cells. 
Crosstab 
 Iron deposition in stromal 
inflammatory cells 
Total 
Absence Presence 
Diagnosis 
Normal 
Count 12 1 13 
% within Diagnosis 92,3% 7,7% 100,0% 
% within Iron deposition in 
stromal inflammatory cells 
33,3% 2,9% 18,6% 
% of Total 17,1% 1,4% 18,6% 
Pure DCIS 
Count 12 12 24 
% within Diagnosis 50,0% 50,0% 100,0% 
% within Iron deposition in 
stromal inflammatory cells 
33,3% 35,3% 34,3% 
% of Total 17,1% 17,1% 34,3% 
Pure IDC 
Count 12 21 33 
% within Diagnosis 36,4% 63,6% 100,0% 
% within Iron deposition in 
stromal inflammatory cells 
33,3% 61,8% 47,1% 
% of Total 17,1% 30,0% 47,1% 
Total 
Count 36 34 70 
% within Diagnosis 51,4% 48,6% 100,0% 
% within Iron deposition in 
stromal inflammatory cells 
100,0% 100,0% 100,0% 
% of Total 51,4% 48,6% 100,0% 
 
Table 12: Pearson’s Chi-square test: differences in iron deposition in epithelial cells 
between sub-groups of lesions. 
Chi-Square Tests 
 Value df Asymp. Sig. (2-
sided) 
Pearson Chi-Square 2,667a 2 ,264 
Likelihood Ratio 2,869 2 ,238 
Linear-by-Linear 
Association 
2,608 1 ,106 
N of Valid Cases 81   
a. 0 cells (0,0%) have expected count less than 5. The minimum 
expected count is 5,70. 
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Table 13: Pearson’s Chi-square test: differences in iron deposition in stromal inflammatory 
cells between sub-groups of lesions. 
Chi-Square Tests 
 Value df Asymp. Sig. (2-
sided) 
Pearson Chi-Square 11,715a 2 ,003 
Likelihood Ratio 13,400 2 ,001 
Linear-by-Linear 
Association 
11,083 1 ,001 
N of Valid Cases 70   
a. 0 cells (0,0%) have expected count less than 5. The minimum 
expected count is 6,31. 
 
Table 14: Pearson’s Chi-square test: differences in iron deposition in stromal inflammatory 
cells between normal and pure DCIS lesions. 
Chi-Square Tests 
 Value df Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square 6,623a 1 ,010   
Continuity Correctionb 4,896 1 ,027   
Likelihood Ratio 7,651 1 ,006   
Fisher's Exact Test    ,013 ,011 
Linear-by-Linear 
Association 
6,444 1 ,011 
  
N of Valid Cases 37     
a. 1 cells (25,0%) have expected count less than 5. The minimum expected count is 4,57. 
 
Table 15: Pearson’s Chi-square test: differences in iron deposition in stromal inflammatory 
cells between normal and pure IDC lesions. 
Chi-Square Tests 
 Value df Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square 11,697a 1 ,001   
Continuity Correctionb 9,563 1 ,002   
Likelihood Ratio 13,370 1 ,000   
Fisher's Exact Test    ,001 ,001 
Linear-by-Linear 
Association 
11,443 1 ,001 
  
N of Valid Cases 46     
a. 0 cells (0,0%) have expected count less than 5. The minimum expected count is 6,22. 
b. Computed only for a 2x2 table 
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Table 16: Pearson’s Chi-square test: differences in iron deposition in stromal inflammatory 
cells between pure DCIS and pure IDC lesions. 
Chi-Square Tests 
 Value df Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square 1,060a 1 ,303   
Continuity Correctionb ,574 1 ,449   
Likelihood Ratio 1,059 1 ,303   
Fisher's Exact Test    ,416 ,224 
Linear-by-Linear 
Association 
1,041 1 ,308 
  
N of Valid Cases 57     
a. 0 cells (0,0%) have expected count less than 5. The minimum expected count is 10,11. 
b. Computed only for a 2x2 table 
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2.2 Iron deposition in adjacent tissue 
 
Table 17: Contingency table demonstrating the frequency and percentage of normal 
samples and samples constituted by histologically “normal” tissue adjacent to DCIS or IDC 
presenting iron deposition in epithelial cells. 
Crosstab 
 Iron deposition in epithelial cells Total 
Absence Presence 
Lesion Diagnosis 
Normal 
Count 18 3 21 
% within Lesion 
Diagnosis 
85,7% 14,3% 100,0% 
% within Iron 
deposition in 
epithelial cells 
40,0% 18,8% 34,4% 
% of Total 29,5% 4,9% 34,4% 
Normal in DCIS 
Count 12 3 15 
% within Lesion 
Diagnosis 
80,0% 20,0% 100,0% 
% within Iron 
deposition in 
epithelial cells 
26,7% 18,8% 24,6% 
% of Total 19,7% 4,9% 24,6% 
Normal in IDC 
Count 15 10 25 
% within Lesion 
Diagnosis 
60,0% 40,0% 100,0% 
% within Iron 
deposition in 
epithelial cells 
33,3% 62,5% 41,0% 
% of Total 24,6% 16,4% 41,0% 
Total 
Count 45 16 61 
% within Lesion 
Diagnosis 
73,8% 26,2% 100,0% 
% within Iron 
deposition in 
epithelial cells 
100,0% 100,0% 100,0% 
% of Total 73,8% 26,2% 100,0% 
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Table 18: Contingency table demonstrating the frequency and percentage of normal 
samples and samples constituted by histologically “normal” tissue adjacent to DCIS or IDC 
presenting iron deposition in stromal inflammatory cells. 
Crosstab 
 Iron deposition in stromal inflammatory 
cells 
Total 
Absence Presence 
Lesion Diagnosis 
Normal 
Count 12 1 13 
% within Lesion 
Diagnosis 
92,3% 7,7% 100,0% 
% within Iron 
deposition in 
stromal 
inflammatory cells 
36,4% 5,3% 25,0% 
% of Total 23,1% 1,9% 25,0% 
Normal in 
DCIS 
Count 9 6 15 
% within Lesion 
Diagnosis 
60,0% 40,0% 100,0% 
% within Iron 
deposition in 
stromal 
inflammatory cells 
27,3% 31,6% 28,8% 
% of Total 17,3% 11,5% 28,8% 
Normal in 
IDC 
Count 12 12 24 
% within Lesion 
Diagnosis 
50,0% 50,0% 100,0% 
% within Iron 
deposition in 
stromal 
inflammatory cells 
36,4% 63,2% 46,2% 
% of Total 23,1% 23,1% 46,2% 
Total 
Count 33 19 52 
% within Lesion 
Diagnosis 
63,5% 36,5% 100,0% 
% within Iron 
deposition in 
stromal 
inflammatory cells 
100,0% 100,0% 100,0% 
% of Total 63,5% 36,5% 100,0% 
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Table 19: Pearson’s Chi-square test: differences in iron deposition in epithelial cells 
between sub-groups of lesions. 
Chi-Square Tests 
 Value df Asymp. Sig. (2-
sided) 
Pearson Chi-Square 4,299a 2 ,117 
Likelihood Ratio 4,317 2 ,116 
Linear-by-Linear 
Association 
3,936 1 ,047 
N of Valid Cases 61   
a. 1 cells (16,7%) have expected count less than 5. The minimum 
expected count is 3,93. 
 
Table 20: Pearson’s Chi-square test: differences in iron deposition in stromal inflammatory 
cells between sub-groups of lesions. 
Chi-Square Tests 
 Value df Asymp. Sig. (2-
sided) 
Pearson Chi-Square 6,618a 2 ,037 
Likelihood Ratio 7,759 2 ,021 
Linear-by-Linear 
Association 
5,945 1 ,015 
N of Valid Cases 52   
a. 1 cells (16,7%) have expected count less than 5. The minimum 
expected count is 4,75. 
 
Table 21: Pearson’s Chi-square test: differences in iron deposition in stromal inflammatory 
cells between normal and “normal” tissue adjacent to DCIS lesions. 
Chi-Square Tests 
 Value df Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square ,206a 1 ,650   
Continuity Correctionb ,000 1 1,000   
Likelihood Ratio ,203 1 ,652   
Fisher's Exact Test    ,677 ,493 
Linear-by-Linear 
Association 
,200 1 ,655 
  
N of Valid Cases 36     
a. 2 cells (50,0%) have expected count less than 5. The minimum expected count is 2,50. 
b. Computed only for a 2x2 table 
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Table 22: Pearson’s Chi-square test: differences in iron deposition in stromal inflammatory 
cells between normal and “normal” tissue adjacent to IDC lesions. 
Chi-Square Tests 
 Value df Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square 6,623a 1 ,010   
Continuity Correctionb 4,896 1 ,027   
Likelihood Ratio 7,651 1 ,006   
Fisher's Exact Test    ,013 ,011 
Linear-by-Linear 
Association 
6,444 1 ,011 
  
N of Valid Cases 37     
a. 1 cells (25,0%) have expected count less than 5. The minimum expected count is 4,57. 
b. Computed only for a 2x2 table 
 
Table 23: Pearson’s Chi-square test: differences in iron deposition in stromal inflammatory 
cells between “normal” tissue adjacent to DCIS lesions and normal tissue adjacent to IDC 
lesions. 
Chi-Square Tests 
 Value df Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square ,371a 1 ,542   
Continuity Correctionb ,078 1 ,780   
Likelihood Ratio ,373 1 ,541   
Fisher's Exact Test    ,742 ,391 
Linear-by-Linear 
Association 
,362 1 ,547 
  
N of Valid Cases 39     
a. 0 cells (0,0%) have expected count less than 5. The minimum expected count is 6,92. 
b. Computed only for a 2x2 table 
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3. IMMUNOHISTOCHEMISTRY 
 
3.1 Epithelial CCL2 expression 
Table 24:  Spearman’s rank correlation test: Epithelial CCL2 expression.  
Correlations 
 CCL2 
expression in 
epithelial cells 
Diagnosis 
Spearman's rho 
CCL2 expression in 
epithelial cells 
Correlation Coefficient 1,000 ,299** 
Sig. (2-tailed) . ,007 
N 80 80 
Diagnosis 
Correlation Coefficient ,299** 1,000 
Sig. (2-tailed) ,007 . 
N 80 83 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
Table 25: Kruskal-Wallis test: differences in epithelial CCL2 expression between sub-
groups of pure lesions. 
Ranks 
 Diagnosis N Mean Rank 
CCL2 expression in 
epithelial cells 
Normal 21 29,17 
Pure DCIS 25 41,40 
Pure IDC 34 46,84 
Total 80  
Test Statisticsa,b 
 CCL2 
expression in 
epithelial cells 
Chi-Square 7,678 
df 2 
Asymp. Sig. ,022 
a. Kruskal Wallis Test 
b. Grouping Variable: Diagnosis 
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Table 26: Dunn-Bonferroni test: differences in epithelial CCL2 expression between sub-
groups of pure lesions. 
 
 
 
 
 
 
 
 
Table 27: Kruskal-Wallis test: differences in epithelial CCL2 expression between normal 
tissue from reduction mammoplasties and histologically “normal” tissue adjacent to 
carcinomas.  
Ranks 
 Diagnosis N Mean Rank 
CCL2 expression in 
epithelial cells 
Normal 21 25,02 
Normal in DCIS 16 35,06 
Normal in IDC 27 36,80 
Total 64  
Test Statisticsa,b 
 CCL2 
expression in 
epithelial cells 
Chi-Square 5,393 
df 2 
Asymp. Sig. ,067 
a. Kruskal Wallis Test 
b. Grouping Variable: Diagnosis 
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3.2 CCL2 expression in macrophages 
 
Table 28: Spearman’s rank correlation test: infiltration of CCL2-positive macrophages. 
Correlations 
 Infiltration of 
CCL2-positive 
macrophages 
Diagnosis 
Spearman's rho 
Infiltration of CCL2-positive 
macrophages 
Correlation Coefficient 1,000 ,335** 
Sig. (2-tailed) . ,004 
N 74 74 
Diagnosis 
Correlation Coefficient ,335** 1,000 
Sig. (2-tailed) ,004 . 
N 74 83 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
Table 29: Kruskal-Wallis test: differences in the infiltration of CCL2-positive macrophages 
between pure sub-groups of lesions. 
Ranks 
 Diagnosis N Mean Rank 
Infiltration of CCL2-positive 
macrophages 
Normal 19 18,89 
Pure DCIS 23 47,96 
Pure IDC 32 41,03 
Total 74  
Test Statisticsa,b 
 Infiltration of 
CCL2-positive 
macrophages 
Chi-Square 20,618 
df 2 
Asymp. Sig. ,000 
a. Kruskal Wallis Test 
b. Grouping Variable: Diagnosis 
 
 
 
 
 
- 121 - 
 
Table 30: Dunn-Bonferroni test: differences in the infiltration of CCL2-positive macrophages 
between sub-groups of pure lesions. 
 
 
 
 
 
 
 
 
Table 31: Kruskal-Wallis test: differences in the infiltration of CCL2-positive macrophages 
between normal tissue from reduction mammoplasties and histologically “normal” tissue 
adjacent to carcinomas. 
Ranks 
 Diagnosis N Mean Rank 
Infiltration of CCL2-positive 
macrophages 
Normal 19 22,79 
Normal in DCIS 12 36,33 
Normal in IDC 24 27,96 
Total 55  
Test Statisticsa,b 
 Infiltration of 
CCL2-positive 
macrophages 
Chi-Square 5,342 
df 2 
Asymp. Sig. ,069 
a. Kruskal Wallis Test 
b. Grouping Variable: Diagnosis 
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3.3 CD68 expression 
 
Table 32: Spearman’s rank correlation test: total macrophage infiltration. 
Correlations 
 Diagnosis Total 
macrophage 
infiltration 
Spearman's rho 
Diagnosis 
Correlation Coefficient 1,000 ,630** 
Sig. (2-tailed) . ,000 
N 83 75 
Total macrophage infiltration 
Correlation Coefficient ,630** 1,000 
Sig. (2-tailed) ,000 . 
N 75 75 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
Table 33: Kruskal-Wallis test: differences in total macrophage infiltration between sub-
groups of pure lesions. 
Ranks 
 Diagnosis N Mean Rank 
Total macrophage infiltration 
Normal 18 14,89 
Pure DCIS 23 37,70 
Pure IDC 34 50,44 
Total 75  
Test Statisticsa,b 
 Total 
macrophage 
infiltration 
Chi-Square 31,333 
df 2 
Asymp. Sig. ,000 
a. Kruskal Wallis Test 
b. Grouping Variable: Diagnosis 
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Table 34: Dunn-Bonferroni test: differences in the total macrophage infiltration between 
sub-groups of pure lesions. 
 
 
 
 
 
 
 
 
Table 35: Kruskal-Wallis test: differences in the total macrophage infiltration between 
normal tissue from reduction mammoplasties and histologically “normal” tissue adjacent to 
carcinomas. 
Ranks 
 Diagnosis N Mean Rank 
Total macrophage infiltration 
Normal 18 22,17 
Normal in DCIS 13 33,65 
Normal in IDC 26 31,40 
Total 57  
Test Statisticsa,b 
 Total 
macrophage 
infiltration 
Chi-Square 4,619 
df 2 
Asymp. Sig. ,099 
a. Kruskal Wallis Test 
b. Grouping Variable: Diagnosis 
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4. STATISTICAL ANALYSIS 
 
Table 36:  Spearman’s rank correlation test: epithelial CCL2 expression and total 
macrophage infiltration. 
Correlations 
 CCL2 
expression in 
epithelial cells 
Total 
macrophage 
infiltration 
Spearman's rho 
CCL2 expression in 
epithelial cells 
 1,000 ,060 
 . ,609 
 80 75 
 
Table 37:  Spearman’s rank correlation test: epithelial CCL2 expression and infiltration of 
CCL2-positive macrophages. 
Correlations 
 CCL2 
expression in 
epithelial cells 
Infiltration of 
CCL2-positive 
macrophages 
Spearman's rho 
CCL2 expression in 
epithelial cells 
 1,000 ,267 
 . ,022 
 80 73 
 
 
Table 38:  Spearman’s rank correlation test: infiltration of CCL2-positive macrophages and 
total macrophage infiltration.  
Correlations 
 Infiltration of 
CCL2-positive 
macrophages 
Total 
macrophage 
infiltration 
Spearman's rho 
Infiltration of CCL2-positive 
macrophages 
 1,000 ,488 
 . ,000 
 75 73 
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Table 39:  Mann-Whitney test: differences in epithelial CCL2 expression, regarding the 
presence of hemosiderin deposition in epithelial cells. 
Test Statisticsa 
 CCL2 
expression in 
epithelial cells 
Mann-Whitney U 721,500 
Wilcoxon W 1946,500 
Z -,137 
Asymp. Sig. (2-tailed) ,891 
a. Grouping Variable: Iron deposition in 
epithelial cells 
 
Table 40:  Mann-Whitney test: differences in epithelial CCL2 expression, regarding the 
presence of hemosiderin deposition in stromal inflammatory cells. 
Test Statisticsa 
 CCL2 
expression in 
epithelial cells 
Mann-Whitney U 323,500 
Wilcoxon W 788,500 
Z -3,177 
Asymp. Sig. (2-tailed) ,001 
a. Grouping Variable: Iron deposition in 
stromal inflammatory cells 
 
Table 41:  Mann-Whitney test: differences in ferroportin 1 expression in lymphocytes, 
regarding the presence of hemosiderin deposition in epithelial cells. 
Test Statisticsa 
 Ferroportin 1 
expression in 
lymphocytes 
Mann-Whitney U 321,500 
Wilcoxon W 849,500 
Z -1,042 
Asymp. Sig. (2-tailed) ,298 
a. Grouping Variable: Iron deposition in 
epithelial cells 
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Table 42:  Mann-Whitney test: differences in ferroportin 1 expression in lymphocytes, 
regarding the presence of hemosiderin deposition in stromal inflammatory cells. 
Test Statisticsa 
 Ferroportin 1 
expression in 
lymphocytes 
Mann-Whitney U 302,500 
Wilcoxon W 512,500 
Z -,837 
Asymp. Sig. (2-tailed) ,403 
a. Grouping Variable: Iron deposition in 
stromal inflammatory cells 
 
Table 43:  Mann-Whitney test: differences in ferroportin 1 expression in macrophages, 
regarding the presence of hemosiderin deposition in epithelial cells. 
Test Statisticsa 
 Ferroportin 1 
expression in 
macrophages 
Mann-Whitney U 356,000 
Wilcoxon W 884,000 
Z -,467 
Asymp. Sig. (2-tailed) ,640 
a. Grouping Variable: Iron deposition in 
epithelial cells 
 
Table 44:  Mann-Whitney test: differences in ferroportin 1 expression in macrophages, 
regarding the presence of hemosiderin deposition in stromal inflammatory cells. 
Test Statisticsa 
 Ferroportin 1 
expression in 
macrophages 
Mann-Whitney U 286,000 
Wilcoxon W 496,000 
Z -,975 
Asymp. Sig. (2-tailed) ,329 
a. Grouping Variable: Iron deposition in 
stromal inflammatory cells 
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Table 45:  Pearson’s Chi-square test: differences in the distribution of the C282Y variants 
between sub-groups of lesions. 
Chi-Square Tests 
 Value df Asymp. Sig. (2-
sided) 
Pearson Chi-Square 3,954a 2 ,138 
Likelihood Ratio 6,314 2 ,043 
Linear-by-Linear 
Association 
3,336 1 ,068 
N of Valid Cases 76   
a. 3 cells (50,0%) have expected count less than 5. The minimum 
expected count is 2,37. 
 
Table 46:  Pearson’s Chi-square test: analyzing differences in the distribution of the H63D 
variants between sub-groups of lesions. 
Chi-Square Tests 
 Value df Asymp. Sig. (2-
sided) 
Pearson Chi-Square 1,937a 2 ,380 
Likelihood Ratio 1,975 2 ,372 
Linear-by-Linear 
Association 
,029 1 ,866 
N of Valid Cases 65   
a. 0 cells (0,0%) have expected count less than 5. The minimum 
expected count is 8,48. 
 
Table 47:  Pearson’s Chi-square test: differences in the distribution of the H63D variants 
with the presence of iron deposition in epithelial cells. 
Chi-Square Tests 
 Value df Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square ,664a 1 ,415   
Continuity Correctionb ,314 1 ,575   
Likelihood Ratio ,668 1 ,414   
Fisher's Exact Test    ,455 ,288 
Linear-by-Linear 
Association 
,654 1 ,419 
  
N of Valid Cases 65     
a. 0 cells (0,0%) have expected count less than 5. The minimum expected count is 11,60. 
b. Computed only for a 2x2 table 
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Table 48:  Pearson’s Chi-square test: differences in the distribution of the H63D variants 
with the presence of iron deposition in stromal inflammatory cells. 
Chi-Square Tests 
 Value df Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square 1,542a 1 ,214   
Continuity Correctionb ,941 1 ,332   
Likelihood Ratio 1,544 1 ,214   
Fisher's Exact Test    ,280 ,166 
Linear-by-Linear 
Association 
1,514 1 ,219 
  
N of Valid Cases 56     
a. 0 cells (0,0%) have expected count less than 5. The minimum expected count is 10,71. 
b. Computed only for a 2x2 table 
 
Table 49:  Mann-Whitney test: differences in the median expression of CCL2 between 
H63D variants. 
Test Statisticsa 
 CCL2 
expression in 
epithelial cells 
Mann-Whitney U 430,000 
Wilcoxon W 808,000 
Z -,606 
Asymp. Sig. (2-tailed) ,545 
a. Grouping Variable: H63D_grouped 
 
Table 50: Mann-Whitney test: differences in the median expression of CCL2 regarding the 
ER-status, in DCIS samples. 
Test Statisticsa 
 CCL2 
expression in 
epithelial cells 
Mann-Whitney U 25,000 
Wilcoxon W 196,000 
Z -2,305 
Asymp. Sig. (2-tailed) ,021 
Exact Sig. [2*(1-tailed Sig.)] ,021b 
a. Grouping Variable: Estrogen Receptor DCIS 
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Table 51: Mann-Whitney test: differences in the median expression of CCL2 regarding the 
ER-status, in IDC samples. 
Test Statisticsa 
 CCL2 
expression in 
epithelial cells 
Mann-Whitney U 60,500 
Wilcoxon W 411,500 
Z -,848 
Asymp. Sig. (2-tailed) ,397 
Exact Sig. [2*(1-tailed Sig.)] ,408b 
a. Grouping Variable: Estrogen Receptor IDC 
b. Not corrected for ties. 
 
Table 52: Spearman’s rank correlation test: CCL2 expression and leukocyte count. 
Correlations 
 CCL2 
expression in 
epithelial cells 
Monocytes Total 
leukocytes 
Lymphocyte
s 
Spearman's rho 
CCL2 expression in 
epithelial cells 
 1,000 ,266 ,009 -,023 
 . ,050 ,950 ,867 
 80 55 55 55 
 
Table 53: Mann-Whitney test: differences in the median expression of CCL2 regarding the 
PR-status, in DCIS samples. 
Test Statisticsa 
 CCL2 
expression in 
epithelial cells 
Mann-Whitney U 57,000 
Wilcoxon W 162,000 
Z -1,097 
Asymp. Sig. (2-tailed) ,273 
Exact Sig. [2*(1-tailed Sig.)] ,291b 
a. Grouping Variable: Progesterone Receptor 
DCIS 
b. Not corrected for ties. 
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Table 54: Mann-Whitney test: differences in the median expression of CCL2 regarding the 
PR-status, in IDC samples. 
Test Statisticsa 
 CCL2 expression 
in epithelial cells 
Mann-Whitney U 87,000 
Wilcoxon W 318,000 
Z -1,134 
Asymp. Sig. (2-tailed) ,257 
Exact Sig. [2*(1-tailed Sig.)] ,271b 
a. Grouping Variable: Progesterone Receptor IDC 
 
Table 55: Mann-Whitney test: differences in the median expression of CCL2 regarding the 
HER-2 status. 
Test Statisticsa 
 CCL2 
expression in 
epithelial cells 
Mann-Whitney U 310,000 
Wilcoxon W 500,000 
Z -,568 
Asymp. Sig. (2-tailed) ,570 
a. Grouping Variable: HER-2 status 
 
Table 56: Mann-Whitney test: differences in the median expression of CCL2 regarding 
lymph node involvement. 
Test Statisticsa 
 CCL2 
expression in 
epithelial cells 
Mann-Whitney U 126,500 
Wilcoxon W 316,500 
Z -,237 
Asymp. Sig. (2-tailed) ,812 
Exact Sig. [2*(1-tailed Sig.)] ,815b 
. Grouping Variable: Lymph node involvement 
 
